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1. INTRODUCTION 
1.1 Immediate Release (IR) Preparations:1, 2 
              The Oral route of administration still continues to be the most preferred 
route due to its manifold advantages including ease of administration, accurate 
dosage, self-medication, versatility and most importantly patient compliance. 
Therefore, oral solid dosage forms are more popular. 
 
              These preparations are primarily intended to achieve faster onset of action 
for drugs such as analgesics, antipyretics, and coronary vasodilators. It is designed 
to disintegrate and release their medicaments with no special rate controlling 
features. Other advantages include enhanced oral bioavailability through 
transmucosal delivery and pregastric absorption, convenience in drug 
administration to dysphasic patients, especially the elderly and bedridden, and new 
business opportunities. 
                   Conventional IR formulations include fast disintegrating tablets and 
granules that use effervescent mixtures, such as sodium carbonate (or sodium 
bicarbonate) and citric acid (or tartaric acid), and superdisintegrants, such as 
sodium starch glycolate, croscarmellose sodium and crospovidone. Current 
technologies in fast-dispersing dosage forms include modified tableting systems, 
floss or Shear form technology, which employs application of centrifugal force and 
controlled temperature and  freeze-drying. 
 Immediate release drug delivery system is a conventional type of drug 
delivery. These are the dosage forms in which ≥ 85% of labelled amount dissolves 
with in 30 min. However for immediate release tablets, tablet disintegrants play an 
important role in ensuring that the tablet matrix break up on contact with fluid in 
the stomach to allow the release the active drug which then become available in 
whole or in part, for absorption from gastrointestinal tract. 
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Advantages of immediate release drug delivery system:  
 Release the drug immediately. 
 More flexibility in adjusting the dose. 
 It can be prepared with minimum dose of drug. 
 There is no dose dumping problem 
 Immediate release drug delivery systems can be used in both 
initial stage and final stage of disease. 
1.2 Current technologies in oral drug delivery:3 
 Over the last 3 decades, many novel oral drug therapeutic systems have 
been invented along with the appreciable development of drug delivery 
technology. Although these advanced DDS are manufactured or fabricated in 
traditional pharmaceutical formulations such as Tablets, Capsules, Sachets, 
Suspensions, Emulsions, and Solutions, they are superior to the conventional oral 
dosage forms in terms of their therapeutic efficacies, toxicities, and stabilities.  
 Based on the desired therapeutic objectives, oral DDS may be assorted 
into three categories:  
• Immediate-release preparations,  
• Controlled-release preparations and        
• Targeted- release preparations.  
1.3 Excipients used in tablets4 
Excipients are inert substances used as diluents or vehicles for a drug. In the 
pharmaceutical industry many exciepients are used. All of these must meet certain 
criteria as follows:- 
 They must be physiological inert. 
 They must be acceptable to regulatory agencies 
 They must be physiologically and chemically stable. 
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 They must be free of any bacteria considered to be pathogenic or otherwise    
objectionable. 
 They must be not interfere with the bioavailability of the drug. 
 They must be commercially available in the form and purity commensurate 
to pharmaceutical standards. 
 Cost must be relatively inexpensive. 
 
                       To assure that no excipient interferences with the utilization of the 
drug, the formulator must carefully and critically evaluate combinations of the 
drug with each of the contemplated excipients and must ascertain compliance of 
each ingredient with existing standards and regulations. 
                       The screening of drug-excipients and excipient-excipient 
interactions should be carried out routinely in preformulations studies.  
1.3.1 Fillers (Diluents) 
Tablet fillers of comprise a heterogeneous group of substances. Since they often 
comprise the bulk of the tablet, selection of a candidate from this group as a carrier 
for a drug is of prime importance.  
1.3.2 Binders 
Binders are the glue that holds powders together to form granules. They are the 
adhesives that are added to tablet formulations to provide the cohesiveness 
required for that bonding together of the granules under compaction to form a 
tablet. The quantity used and the method of application must be carefully 
regulated, since the tablet must remain intact when swallowed and then release its 
medicament. 
1.3.3 Lubricants 
Lubricants are used in tablet formulation to ease the ejection of the tablet from the 
die, to prevent sticking of tablets to the punches, and to prevent excessive wear on 
punches and dies. They function by interposing a film of low shear strength at the 
interface between the tablet and the die wall and the punch face.         
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In selecting a lubricant, the following should be considered: 
 Lubricants markedly reduce the bonding properties of many excipients.  
 Over blending is one of the main causes of lubrication problems. 
Lubricants should be added last to the granulation and tumble-blended for 
not more than 10 min. 
 Lubricant efficiency is a function of particle size; therefore, the finest grade 
available should be used and screened through a 100-300 mesh screen 
before use. 
 Examples of lubricants commonly used are magnesium stearate,  talc, 
starch. 
1.3.4 Disintegrants 
Disintegrants are used in tablet preparation to break the tablet faster. But some of 
the disintegrants are also having property of enhancing solubility of insoluble drug. 
 Bioavailability of a drug depends in absorption of the drug, which is 
affected by solubility of the drug in gastrointestinal fluid and permeability of the 
drug across gastrointestinal membrane. The drugs solubility mainly depends on 
physical – chemical characteristics of the drug. However, the rate of drug 
dissolution is greatly influenced by disintegration of the tablet. 
 The drug will dissolve at a slower rate from a non disintegrating tablet 
due to exposure of limited surface area to the fluid. The disintegration test is an 
official test and hence a batch of tablet must meet the stated requirements of 
disintegration. 
 Disintegrants, an important excipient of the tablet formulation, is 
always added to tablet to induce breakup of tablet when it comes in cling pressure 
exerted in the outer direction or radial direction, it causes tablet to burst or the 
accelerated absorption of water leading to an enormous increase in the volume of 
granules to promote disintegration. 
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1.4 Tablet manufacturing methods:5,6 
       There are three basic methods of manufacturing:  
 Direct Compression 
 Dry granulation 
 Wet granulation 
 Fluidized bed granulation 
Granulation: 
Introduction:- 
      Granulation process has been widely used in the pharmaceutical industry for 
the preparation of material for tableting. Other process which involves the granule 
formation includes microencapsulation, multi-particulate system for modified 
release mechanism and to prepare granules to be used by patient directly. Primarily 
granules are prepared to improve flow and compression characteristics of the blend 
but there are many other reasons and sometimes multiple reasons for granulation 
such as- 
 Improving flow properties of the mix and hence the uniformity of the dose 
 Increasing the bulk density of a product 
 Facilitating metering or volumetric dispensing 
 Controlling the rate of drug release 
 Decrease dust generation and reduce employee exposure to drug product 
 Improving product appearance 
 
Reasons for Granulation  
1) To prevent segregation of the constituents of the powder mix 
          Segregation (or demixing) is primarily due to differences in the size or 
density of the components of the mix. 
 The smaller or denser particles concentrating at the base of a container. 
 The larger or less dense ones above them. 
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 An ideal granulation will contain all the constituents of the mix in the 
correct proportion in each granule and segregation of the ingredients will 
not occur. 
  
2) To improve the flow properties of the mix 
Many powders because of their small size irregular shape and surface 
characteristics are cohesive and don’t flow well. Poor flow will often result 
in a wide weight variation with in the final product owing to variable fill of 
tablet dies etc. 
3) To improve the compaction characteristics of the mix 
The granulation of toxic materials will reduce the hazard associated with 
the generation of toxic dust that may arise when handling powders. 
1.4.1 Direct Compression 
 This method is used when a group of ingredients can be blended and 
placed in a tablet press to make a tablet without any of the ingredients having to be 
changed. This is not very common because many tablets have active 
pharmaceutical ingredients which will not allow for direct compression due to their 
concentration or the excipients used in formulation are not conducive to direct 
compression. 
 Granulation is the process of collecting particles together by creating 
bonds between them. There are several different methods of granulation. The most 
popular, which is used by over 70% of formulation in tablet manufacture is wet 
granulation. Dry granulation is another method used to form granules. 
1.4.2 Wet granulation: 
Wet granulation is the most widely used process of granulation in the 
pharmaceutical industry. It involves addition of a liquid solution (with or without 
binder) to powders, to form a wet mass or it forms granules by adding the powder 
together with an adhesive, instead of by compaction. The wet mass is dried and 
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then sized to obtained granules. The liquid added binds the moist powder particles 
by a combination of capillary and viscous forces in the wet state. More permanent 
bonds are formed during subsequent drying which leads to the formation of 
agglomerates. 
Important steps involved in the wet granulation 
 Mixing of the drug(s) and excipients 
 Preparation of binder solution 
 Mixing of binder solution with powder mixture to form wet mass. 
 Coarse screening of wet mass using a suitable sieve (6-12 screens). 
 Drying of moist granules. 
 Screening of dry granules through a suitable sieve (14-20 screens). 
 Mixing of screened granules with disintegrant, glidant and lubricant. 
 Compression of lubricated granules to tablet. 
1.5 Tablet coating 7, 8 
         Coated tablets are defined as the tablets covered with one or more layers of 
mixture of various substances such as natural or synthetic resins, gums, inactive 
and insoluble filler, sugar, plasticizer, polyhydric alcohol, waxes, authorized 
coloring material coating may also contain active ingredient. Substances used for 
coating are usually applied as solution or suspension under conditions where 
vehicle evaporates. 
The purpose of tablet coating:  
1. Cover the unpleasant taste, odor and color  
2. Physical and chemical protection in medicine from environment (light, moisture, 
and air) 
3. Control of drug release as in enteric coating or sustained release 
4. Improve the appearance of tablets  
5. Assist and facilitate the identification of drug 
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6. Easing the process of blistering 
Basic principles of tablet coating: 
 Insulation which influences the release pattern as little as possible and does not 
markedly change the appearance. 
 Modified release with specific requirements and release mechanism adapted to 
body function in the digestive tract. 
 Color coating which provides insulation or is combined with modified release 
coating. 
Types of tablet coating process: 
1. Sugar coating 
2. Film coating 
3. Enteric coating 
4. Controlled release coating 
5. Specialized coating 
6. Compressed coating 
7. Electrostatic coating 
8. Dip coating 
9. Vacuum film coating 
1.5.1 Film coating: 
                   Film coating is deposition of a thin film of polymer surrounding the 
tablet core. Conventional Pan Equipment’s may be used but now a day’s more 
sophisticated equipment’s are employed to have a high degree of automation and 
coating time. 
Advantages of film coating: 
 It is a less time consuming technique. 
 Not much labor is required. 
 It has no adverse effects on disintegration of tablets. 
 The product cost is low because the material used for coating is quite 
cheap. 
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 It protects the drug from atmosphere changes such as light, air, and 
moisture 
 Coating is resistant to cracking and chipping. 
 Film coating of tablets does not increase the weight of the tablet. 
 No water proof coating is required before the actual film coating. 
 The tablets become elegant. 
Ideal film coating materials: 
 Solubility in solvents of choice for coating preparation. 
 Solubility required for the intended. Use, e.g.; free water solubility, slow 
water solubility or pH-dependent solubility. 
 Capacity to produce an elegant looking product. 
 Stability in the presence of heat, light, moisture, air and the substrate being 
coated, the film properties should not change with aging. 
 Essentially no color, no taste or odor. 
 Compatibility with common coating solution additives. 
 Non-toxicity with no pharmacological activity, and ease of application to 
the particles or tablets. 
 Resistance to cracking and provision of adequate moisture, light, odor or 
drug sublimation barrier when desired. 
 No bridging or filling of these de bossed tablets surface by the film former. 
 Ease of printing procedure on high-speed equipment. 
Process description: 
         Film coating is deposition of a thin film of polymer surrounding the tablet 
core. Conventional pan equipment’s may be used but now a day’s more 
sophisticated equipment’s are employed to have a high degree of automation and 
coating time. The polymer is solubilized in to solvent. Other additives like 
plasticizer and pigments are added. Resulting solution is sprayed on to a rotated 
tablet bed. The drying conditions cause removal of the solvent, giving thin 
deposition material around each tablet core. 
Process details: 
         Usually spray process is employed in preparation of film coated tablets. 
“Accelacota” is the prototype of perforated cylindrical drum providing high drying 
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air capacity. Fluidized bed equipment has made considerable impact where tablets 
are moving in a stream of air passing through the perforated bottom of a cylindrical 
column. With a smaller cylindrical insert, the stream of cores is rising in the center 
of the device together with a spray mist applied in the middle of the bottom. For 
fluidized bed coating, very hard tablets (hardness>20N) have to be used. 
Basic process requirement for film coating: 
         The fundamental requirements are independent of the actual type of 
equipment’s being used and include adequate means of atomizing the spray liquid 
for application to the tablet core, adequate mixing and agitation of tablet bed, 
sufficient heat input in the form of drying air to provide the latent heat of 
evaporation of the solvent. This is particularly important with aqueous-based 
spraying and good exhaust facilities to remove dust and solvent laden air. 
Materials used in film coating 
1. Film formers (which may be enteric or non-enteric) 
2. Solvents 
3. Plasticizers 
4. Colorants 
5. Opaquent extenders 
6. Miscellaneous coating solution components 
I. Film formers: This may be enteric or non-enteric 
Enteric Materials: 
 Cellulose acetate phthalate 
 Acrylate polymer 
 Hydroxy propyl methylcellulose phthalate 
 Polyvinyl acetate phthalate 
Non-enteric material: 
 Hydroxy propyl methylcellulose 
 Ethyl cellulose 
 Hydroxy propylcellulose 
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 Povidone 
 Sodium carboxyl methyl cellulose 
 Polyethylene glycols 
 Acrylate polymer 
. II. Solvents 
         Mostly solvents are used either alone or in combination with water, 
methanol, iso-propanol, chloroform, acetone, methylene chloride etc. Water is 
more used because no environmental and economic considerations. 
III. Plasticizers:         
Commonly used plasticizers are castor oil, PG, glycerin, lower molecular 
weight (200-400 series) PEGS, surfactants etc. For aqueous coating PEGS are 
more used while castor oil and spans are primarily used for organic-solvent based 
coating solution. 
IV. Colorants: 
         These make the dosage form aesthetic and help manufacturers to control 
product during manufacturing and is a means of identification for user. Most 
common colorants in use are certified FD & C or D & C colorants. 
V. Opaquant-Extenders: 
          Most commonly used materials are titanium dioxide, Silicate (talc & 
aluminum silicates), carbonates (magnesium carbonates), Oxides (magnesium 
oxide) & Hydroxides (aluminum hydroxides). 
VI. Miscellaneous coating solution components  
           Flavors, sweeteners, surfactants, antioxidants etc. may be incorporated into 
the coating solution. 
Coating equipments: 
Most of the coating processes use one of three general types of equipment’s.  
 The standard Coating pan 
 The Perforated Coating pan 
 The Fluidized bed coater 
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Important Parameters in Tablet Coating Process:- 
Tablet coating is a complex process that is affected by many variables. Some of 
those variables can be evaluated or controlled, others can’t. Here are some of the 
parameters you should check when evaluating coating process to determine the 
source of defective coated tablets. 
1. Control: Many problems occur in coating when you can’t control every 
important parameter, such as temperature, pan pressure, spray rates, and 
atomization pressure. But, the tablet’s surface temperature can be measure with 
additional tools (out from the coating equipment) by using infra-red thermometer 
(laser thermometer). 
2. Tablet quality: Tablets must have the proper porosity, surface, hardness, and 
moisture content. You can’t have consistent coating without consistent tablet 
quality. 
3. Waiting period: Most tablets cannot be coated immediately after they’ve been 
compressed. The energy within the tablets is still fairly high and they are still 
warm. In addition, tablet hardness changes over 24 to 48 hours. Let the tablets rest 
at least that long before you coat them meanwhile you can check the uncoated 
tablet for assay, dissolution or other specification by quality control. After the QC 
released the tablet, then you can start the coating process. 
Parameters in Film Coating Tablet Process 
4. Batch size: Variation in batch size changes the required pan speed, gun 
geometry, spray rates, and temperature. The more your batch sizes vary the more 
quality issues that will arise in the coating process. Usually, the greater batch size 
or the greater number of tablets in pan coating the pan speed to spin faster. Vice 
versa, if the number of tablets or the smaller the batch size, pan speeds spin also 
reduced. 
5. Coating Solution preparation: Track the solution temperature, mixer speed, 
and storage time.  Standard operation procedure for the coating solution 
manufacturing should be there. 
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6. Spray gun calibration: We should calibrate or check the calibration of the guns 
every time you change products. This means checking the gun’s overall condition 
and its filter, nozzle alignment, and needle condition. 
7. Spray Gun Position/Geometry: Geometry refers to the gun-to-gun alignment, 
gun-to-tablet bed alignment, and distance from the gun to the end of the pan. 
Furthermore, make sure all the guns are pointed in exactly the same direction and 
are maintaining the same spray pattern. Make certain that the tubing and 
connections are tight and do not interfere with alignment. 
8. Gun nozzles: The spray gun nozzles must be kept clean and free of product 
buildup. Use a flashlight during coating to look into the cabinet and check the 
nozzles. 
9. Pan loading: A visual inspection is critical when coating tablets that are friable 
or that chip or break easily. That’s why, while loading the tablets, we can search 
for tablets that are broken, capped, chipped, or covered with black speck and check 
for any defects that occur. We can also check the tablets during initial pan rotation, 
or after preheating. 
10. Cleaning: Each component of the spraying system should be cleaned and dried 
before re-installing it after a product changeover. In tablet coating, small changes 
in almost any parameter can lead to big differences in results. The more consistent 
you make operations, and the tablet, the less you must rely on the skill of the 
operator. Coating may be something of an art, but you’ll get better results when 
you apply a little science to it. 
1.6 Immediate release preparations: 
1.6.1 Mechanism of drug release:9 
 On exposure to aqueous fluids, hydrophilic matrices take up water and 
the polymer starts hydrating to form a gel layer. Drug release is controlled by 
diffusion barriers/ by surface erosions. An initial burst of soluble drug may occur 
due to surface leaching  when a matrix containing a swellable glassy polymer 
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comes in to contact with an aqueous medium, there is an abrupt change from a 
glassy to rubbery state associate with swelling process with time, water infiltration 
deep in to a case increasing the thickness by the gel layer. The outer layer becomes 
fully hydrated and starts dissolving or eroding. When water reaches the center of 
the system and the concentration of drug falls below the solubility value, the 
release rate of the drug begins to reduce. At the same time an increase in thickness 
of the barrier layer with time increases the diffusion path length, reducing the rate 
of drug release.   
1.6.2 Super disintegrants in immediate release:10 
 These are especially important for an immediate release product where 
rapid release of dug substance is required. A disintegrant can be added to powder 
blend for direct compression.  
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                                  Table 1: List of Super Disintegrants 
 
 
Super Disintegrants   Example of Mechanism of 
Action 
Special comment 
Croscarmellose 
Ac-Di-Sol 
Nymeee ZSX 
Primellose 
Solutab 
Vivasol 
 
Cross linked    
  cellulose 
 
Swells 4-8 folds in 
< 10 seconds. 
Swelling and 
wicking both 
 
Swells in two 
dimensions 
Direct compression 
or granulation 
-Starch free 
 
Crospovidone 
Crospovidon M 
Kollidon 
Polyplasodone 
 
 
Crosslinked 
PVP 
 
Swells very little 
and returns to 
original size after 
compression but 
act by capillary 
action 
 
Water insoluble and 
spongy in nature so 
get porous tablet 
 
Sodium starch 
glycolate  
  Explotab 
  Primogel 
 
Crosslinked     
     Starch 
 
Swells 7-12 folds 
in  < 30 seconds 
 
Swells in three 
dimensions and 
high level serve as 
sustain release 
matrix 
 
Alginic acid NF 
Satialgine 
 
Cross linked  
Alginic acid 
 
Rapid swelling in 
aqueous medium 
or wicking action 
 
Promote 
disintegration in 
both dry or wet 
granulation. 
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1.6.3 Mechanism Of Tablet Disintegration:11 
 Disintegrants, an important excipient of the tablet formulation, are 
always added to tablet to induce breakup of tablet when it comes in contact with 
aqueous fluid and this process of desegregation of constituent particles before the 
drug dissolution occurs, is known as disintegration process and excipients which 
induce this process are known as disintegrants. [Shangraw RF, et, al., 1980]. 
The tablet breaks to primary particles by one or more of the mechanisms: 
 capillary action (Wicking) 
 swelling 
 Due to deformation 
 Due to release of gases 
Capillary action (Wicking) 
 Effective disintegrants that do not swell are believed to impart their 
disintegrating action through porosity and capillary action. Tablet porosity 
provides way for the penetration of fluid into tablets. The disintegrant particles 
(with cohesiveness and compressibility) themselves act to enhance porosity and 
provide these capillaries into the tablet. Liquid is drawn up or leak into these ways 
by capillary action and rupture the inter-particulate bonds causing the tablet to 
break into small particles 
Swelling   
                 Not all disintegrants swell in contact with water swelling is believed to 
be a mechanism in which; certain disintegrating agents (like starch) impart their 
disintegrating effect. By swelling on contact with water the adhesiveness of other 
ingredients in a tablet is overcome causing the tablet to disintegrate. 
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Figure-1: Mechanism of Disintegration by Wiciking and Swelling12 
Due to deformation:                                                                                                           
 Starch grains are generally thought to be “elastic” in nature that is the 
grains that are deformed under pressure will return to their original shape when 
that pressure is removed. But, with the compression force involved in tabletting, 
these grains are permanently deformed and are said to be “Energy Rich” with these 
energy being released upon exposure to water, i.e. the ability for starch to swell is 
higher in “Energy Rich starch” grains than in starch grains that have not been 
deformed under pressure. It is believed that no single mechanism is responsible for 
the action of most disintegrants. But rather, it is more likely the result of inter-
relationships between these major mechanisms 
Particles swell and break up the matrix 
from within; swelling sets up; localized 
stress spreads throughout the matrix. 
Water is pulled into pores by 
disintegrants and reduces the physical 
bonding between particles. 
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Particles swell to precompression size and break up the matrix 
Figure-2: Mechanism of tablet disintegration by deformation 
Due to release of gases: 
 Carbon dioxide released within tablets on wetting due to interaction 
between bicarbonate and carbonate with citric acid or tartaric acid. The tablet 
disintegrates due to generation of pressure within the tablet. This effervescent 
mixture is used when we needs to formulate very rapidly dissolving tablets or fast 
disintegrating tablets. 
1.7 Biopharmaceutics Classification System: 
The Biopharmaceutics Classification System is a guide for predicting the intestinal 
drug absorption provided by the U.S Food and Drug Administration. 
            This system restricts the prediction using the parameters solubility and 
intestinal permeability. The solubility classification is based on a United States 
Pharmacopoeia (USP) aperture. The intestinal permeability classification is based 
on a comparison to the intravenous injection. All those factors are highly important 
because 85% of the most sold drugs in the United States and Europe are orally 
administered. 
According to the Biopharmaceutics Classification System, drug substances are 
classified as follows: 
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 Class I - high permeability, high solubility  
                    Those compounds are well absorbed and their absorption rate is 
usually higher than excretion. 
 Class II - high permeability, low solubility  
                   The bioavailability of those products is limited by their solvation rate. 
A correlation between the in vivo bioavailability and the in vitro solvation can be 
found. 
 Class III - low permeability, high solubility  
                  The absorption is limited by the permeation rate but the drug is solvated 
very fast. If the formulation does not change the permeability or gastro-intestinal 
duration time, then class I criteria can be applied. 
 Class IV - low permeability, low solubility  
               Those compounds have a poor bioavailability. Usually they are not well 
absorbed over the intestinal mucosa and a high variability is expected. 
The drugs are classified in BCS on the basis of following parameters: 
1. Solubility 
2. Permeability 
3. Dissolution 
The class boundaries for these parameters are: 
1. Solubility class boundaries- It is based on the highest dose strength of an 
immediate release product. A drug is considered highly soluble when the highest 
dose strength is soluble in 250 ml or less of aqueous media over the pH range of 1 
to 7.5. The volume estimate of 250 ml is derived from typical bioequivalence study 
protocols that prescribe administration of a drug product to fasting human 
volunteers with a glass of water. 
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2. Permeability class boundaries- It is based indirectly on the extent of 
absorption of a drug substance in humans and directly on the measurement of rates 
of mass transfer across human intestinal membrane. Alternatively non-human 
systems capable of predicting drug absorption in humans can be used (such as in-
vitro culture methods). A drug substance is considered highly permeable when the 
extent of absorption in humans is determined to be 90% or more of the 
administered dose based on a mass-balance determination or in comparison to an 
intravenous dose. 
3. Dissolution class boundaries- An immediate release product is considered 
rapidly dissolving when no less than 85% of the labeled amount of the drug 
substance dissolves within 15 minutes using USP Dissolution Apparatus 1 at 100 
RPM or Apparatus 2 at 50 RPM in a volume of 900 ml or less in the following 
media: 0.1 N HCl or simulated gastric fluid or pH 4.5 buffer and pH 6.8 buffer or 
simulated intestinal fluid. 
  1.8 Cancer:13, 14 
                   Cancer known medically as a malignant neoplasm, is a broad group of 
various diseases, all involving unregulated cell growth. It is a disease characterized 
by a loss in the normal control mechanisms that govern cell survival, proliferation 
and differentiation. Cells that have undergone neoplastic transformation usually 
express cell surface antigens that may be of normal fetal type, may display other 
signs of apparent immaturity, and may exhibit qualitative or quantitative 
chromosomal abnormalities, including various translocations and the appearance of 
amplified gene sequences. It is now well –established that a small subpopulation of 
cells, referred to as tumour stem cells, reside within a tumour mass. They retain the 
ability to undergo repeated cycles of proliferation as well as to migrate to distant 
sites in the body to colonize various oragans in the process called metastasis. Cells 
divide and grow uncontrollably. It may also spread to more distant parts of the 
body through the lymphatic system or bloodstream. Malignanat neoplasm is 
cancerous while benign neoplasm is not cancerous. The invasive and metastatic 
process as well as a series of  metabolic abnormalities associated with cancer result 
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in tumor-related symptoms and eventual death of the patient unless the neoplasm 
can be eradicated with treatment. There are over 200 different known cancers that 
afflict humans. 
                 Cancer is a leading cause of death group worldwide and accounted for 
7.4 million deaths (around 13% of all deaths) in 2004. Deaths from cancer 
worldwide are projected to continue rising, with an estimated 11.5 million deaths 
in 2030. 
Classification:15 
There are five broad groups that are used to classify cancer 
1. Carcinomas:  
           These are characterized by cells that cover internal and external parts of the    
body, such as lung, breast and colon cancer. 
2. Sarcomas: 
          These are characterized by cells that are located in bone, cartilage, fat, 
connective tissue, muscle and other supportive tissues. 
3. Lymphomas: 
          These are cancers that begin in the lymph nodes and immune system tissues. 
4. Leukemias: 
            These are cancers that begin in the bone marrow and often accumulate in 
the blood stream. 
5. Adenomas: 
            These are cancers that arise in the thyroid, the pituitary gland, the adrenal 
gland and other glandular tissues. 
Risk factors for cancer:16 
• Tobacco use 
• Alcohol use 
• Dietary factors, including insufﬁcient fruit and vegetable intake 
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• Overweight and obesity 
• Physical inactivity  
• Chronic infections from helicobacter pylori, hepatitis B virus (HBV), hepatitis C 
virus (HCV)  and some types of human papilloma virus (HPV) 
• Environmental and occupational risks including ionizing and non-ionizing 
radiation 
Detection17 
           Cancer can be detected in a number of ways, including the presence of 
certain signs and symptoms, screening tests or medical imaging. Once a possible 
cancer is detected it is diagnosed by microscopic examination of a tissue sample. 
The chances of surviving the disease vary greatly by the type and location of the 
cancer and the extent of disease at the start of treatment. Physicians use 
information from symptoms and several other procedures to diagnose cancer. 
Imaging techniques such as X-rays, CT scans, MRI scans, PET scans, endoscopy 
and ultrasound scans are used regularly to detect where a tumor is located and what 
organs may be affected by it. Biopsies and various bio marker tests were also used 
to detect specific cancers 
Treatment:                
           . Cancer treatment depends on the type of cancer, the stage of cancer, age, 
health status and additional personal characteristics. The treatment of most cancer 
patients requires a skillful interdigitation of multiple modalities of treatment. Each 
of these forms of treatment carries its own risks and benefits. 
Cancer is usually treated with  
 Chemotherapy 
 Radiation therapy 
 Surgery Biological therapy 
 Hormone therapy 
 Gene therapy 
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   One of the greatest challenges of therapeutics is to adjust dose to achieve a 
therapeutic, but nontoxic, outcome. While it is customary to base dose on body 
surface area for individual patients, this practice is not based on solid data. Dose 
adjustment based on renal function or on pharmacokinetic monitoring does help 
meet specific targets such as desired drug concentration in plasma or area under the 
concentration-time curve (AUC), a measure of tissue exposure to the agent in 
question. 
1.8.1 Cancer Chemotherapy:18 
              
                Cancer chemotherapy strives to cause a lethal cytotoxic event or 
apoptosis in the cancer cell that can arrest a tumor's progression. The attack is 
generally directed toward DNA or against metabolic sites essential to cell 
replication. For example, the availability of purines and pyrimidines, which are the 
building blocks for DNA or RNA synthesis. The ultimate goal of chemotherapy is 
a cure (that is, long-term, disease-free survival). A true cure requires the 
eradication of every neoplastic cell. If a cure is not attainable, then the goal 
becomes control of the disease (stop the cancer from enlarging and spreading) to 
extend survival and maintain the best quality of life. Earlier diagnosis of cancer 
lead to increased cure rates. In advanced stages of cancer, the likelihood of 
controlling the cancer is far from reality and the goal is palliation (that is, 
alleviation of symptoms and avoidance of life-threatening toxicity). This means 
that chemotherapeutic drugs may be used to relieve symptoms caused by the 
cancer and improve the quality of life, even though the drugs may not lengthen 
life. 
 Indications for treatment: 
 Chemotherapy is indicated when neoplasms are disseminated and are not 
amenable to surgery. 
 It is also used as a supplemental treatment, to attack micrometastases 
following surgery and radiation treatment in which case it is called adjuvant 
chemotherapy. 
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  Chemotherapy given prior to the surgical procedure in an attempt to shrink 
the cancer is referred as neoadjuvant chemotherapy. 
  Chemotherapy given in lower doses to assist in prolonging a remission is 
known as maintenance chemotherapy. 
  Dosage factors:19 
            One of the main factors limiting the ability of chemotherapy to achieve 
cure is the problem of effective dosing. For chemotherapy, therapeutic selectivity 
is dependent on the difference between the dose- response curves of normal and 
tumor tissues. At present, there are three main approaches to dose-intense delivery 
of chemotherapy: 
 By dose escalation where by the doses of the anticancer agents are 
increased. 
 To administer anticancer agents in a dose-intense manner by 
reducing the interval between treatment cycles. 
 Sequential scheduling of either agents or of combination regimens. 
              Each of these strategies is presently being applied to a wide range of 
cancers, and in general, such dose-intense regimens have significantly improves 
clinical outcomes. 
1.8.2 Antineoplastic agent20 
               Antineoplastic agents are the drugs used in the treatment of cancer. The 
two key aspects of cellular life are  
 DNA synthesis and mitosis to produce new cells. 
 Cell differentiation which produces specialized cells. 
               Normally cells have control mechanisms to modulate these two processes 
by growth factor or growth inhibitors. A balance between cell growth and cell 
death is maintained, cell death is actively regulated by process known as 
“apoptosis”. Apoptosis is defined as a process of cell shrinkage, membrane 
blabbing and nuclear condensation. 
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              In cancer cell, this regulatory process is aberrant; they produce over 
production of growth factor and avoid apoptosis which continue to multiply in an 
unregulated manner. The unregulated growth causes damage to DNA, resulting in 
mutations to genes, that encode from protein controlling cell division. 
1.8.3 Classification 
 Antineoplastic agents are classified according to their mechanism of action into: 
 Alkylating agents 
 Antimetabolites 
 Antibiotics 
 Plant products 
 Enzymes 
 Hormones 
 Immunotherapy 
 Monoclonal Antibodies 
 Radiotherapeutic Agents 
 Cytoprotective Agent 
The present drug capecitabine comes under the Antimetabolites class as pyrimidine 
analogue. 
Antimetabolites: 
             They are structurally related to normal compounds that exist within the 
cell. They generally interfere with the availability of normal purine or pyrimidine 
nucleotide precursors, either by inhibiting their synthesis or by competing with 
them in DNA or RNA synthesis. Their maximal cytotoxic effects are in S-phase. 
 Pyrimidine analogues: 
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The structural modification of these metabolites may be on the pyrimidine 
ring. The possible mechanisms of action are 
 Inhibition of kinases or enzyme involved in biosynthesis of pyrimidine. 
 Incorporation into DNA or RNA leading to miscoding. 
 Inhibition of DNA polymerase. 
 
1.8.4 Breast cancer21 
                Breast cancer is a type of cancer originating from breast tissue, most 
commonly from the inner lining of milk ducts or the lobules that supply the ducts 
with milk. Cancers originating from ducts are known as ductal carcinomas, while 
those originating from lobules are known as lobular carcinomas. Breast cancer 
occurs in humans and other mammals. While the overwhelming majority of human 
cases occur in women, male breast cancer can also occur. 
               Breast cancer, like other cancers, occurs because of an interaction 
between the environment and a defective gene. Normal cells divide as many times 
as needed and stop. They attach to other cells and stay in place in tissues. Cells 
become cancerous when mutations destroy their ability to stop dividing, to attach 
to other cells and to stay where they belong. 
                 The management of primary breast cancer has undergone a remarkable 
evolution as a result of major efforts at early diagnosis and the implementation of 
combined modality approaches incorporating systemic chemotherapy as an 
adjuvant to surgery and radiation therapy. 
1.8.5 Colorectal cancer22,23 
                Colorectal cancer, commonly known as colon cancer or bowel cancer, is 
a cancer from uncontrolled cell growth in the colon or rectum (parts of the large 
intestine), or in the appendix. Genetic analysis shows that colon and rectal tumours 
are essentially genetically the same cancer. Symptoms of colorectal cancer 
typically include rectal bleeding and anemia which are sometimes associated with 
weight loss and changes in bowel habits. 
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               Most colorectal cancer occurs due to lifestyle and increasing age with only 
a minority of cases associated with underlying genetic disorders. It typically starts 
in the lining of the bowel and if left untreated, can grow into the muscle layers 
underneath, and then through the bowel wall. Screening is effective at decreasing 
the chance of dying from colorectal cancer. Localized bowel cancer is usually 
diagnosed through sigmoidoscopy or colonoscopy. 
          Cancers that are confined within the wall of the colon are often curable with 
surgery while cancer that has spread widely around the body is usually not curable 
and management then focuses on extending the person's life via chemotherapy and 
improving quality of life.  
Signs and Symptoms: 
           The symptoms and signs of colorectal cancer depend on the location of 
tumor in the bowel and whether it has spread elsewhere in the body. The classic 
warning signs 
 Worsening constipation 
 Blood in stool 
 Weight loss 
 Fever 
 Loss of appetite 
 Nausea or Vomiting 
While rectal bleeding or anemia are high risk features in those over the age of 50. 
Causes 
     Greater than 75-95% of colon cancer occurs in people with little or no genetic 
risk. Other risk factors include older age, male gender, high intake of fat, alcohol 
or red meat, obesity, smoking  and a lack of physical exercise. 
      People with inflammatory bowel disease (ulcerative colitis and Crohn’s 
disease) are at increased risk of colon cancer. The risk is greater the longer a 
person has had the disease and the worse the severity of inflammation 
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         Those with a family history in two or more first degree relatives have a two 
to threefold greater risk of disease and this group accounts for about 20% of all 
cases. A number of genetic syndromes are also associated with higher rates of 
colorectal cancer. 
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2. Literature Review 
 
M. R. Chorawala24 et al., (2012) explained that the management of cancer 
involves surgery, radiotherapy and chemotherapy. Development of 
chemoresistance is a persistent problem during the chemotherapy treatment. 
Cytotoxic drugs that selectively, but not exclusively, target actively proliferating 
cells include such diverse groups as DNA-alkylating agents, anti-metabolites, 
intercalating agents and mitotic inhibitors. Resistance constitutes a lack of response 
to drug-induced tumour growth inhibition Attempts to overcome resistance 
involves the use of combination drug therapy using different classes of drugs with 
minimally overlapping toxicities to allow maximal dosages, necessary for bone 
marrow recovery. Adjuvant therapy with p-glycoprotein inhibitors and in specific 
instances, the use of growth factor and protein kinase C inhibitors are newer 
experimental approaches that may also prove effective in delaying onset of 
resistance. Gene knockout using antisense molecules may be effective way of 
blocking drug resistance. 
 
Jigar A Patel25 et al., (2011) The task of developing Immediate release tablet is 
accomplished by using a suitable diluents and super disintegrants. Faster 
disintegration of the tablet administrated orally minimizes absorption time and 
improves its bioavailability in less time. Immediate Release tablet of Antibiotic 
drug is formulated using dry granulation using super disintegrant croscarmellose 
sodium. Azithromycin is Antibiotic drug is used to treat STDs due to Chlamydia 
and gonorrhea, community-acquired pneumonia, pelvic inflammatory disease, 
pediatric otitis media and pharyngitis, and Mycobacterium avium complex (MAC) 
in patients with advanced HIV disease. One of the important studies included in 
the present investigation is of study on process parameter effect on performance of 
the Immediate Release tablets. The effect of selected process parameters on critical 
properties of Immediate release (IR) tablets were studied, like effect of 
disintegration time, friability, dissolution profile. 
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Biljana Govedarica26 et al., (2011) Paracetamol (PAR) crystals exhibit poor 
compressibility, flow ability. To improve the mechanical strength of tablets several 
kinds of “Paracetamol for direct compression” are present on the market. Current 
research demonstrated the best tablet properties with coated Paracetamol 
Furthermore, coated Paracetamol in combination with both investigated super 
disintegrants such as Vivasol® and Polyplasdone® XL-10 shows faster 
disintegration time and dissolution rate in comparison to Paracetamol for direct 
compression. Eventually, the major advantages of the formulation with coated 
Paracetamol for industrial production are decrease of friability and superiority in 
terms of flowability, compressibility, quick disintegration and dissolution. 
Nansri Saha Ghosh27 et al., (2011) The “objective” of this project work was to 
formulate a stable safe and effective film coated Immediate release solid dosage 
form of “Ranitidine HCl” that spontaneously release the drug when expose into 
GIT for producing anti-ulcer effect. One of the major steps in formulation 
development activity is the development of “Film coating formulation and 
process” using hydroxyl propyl methyl cellulose (HPMC-2208) and starch acetate 
film former. 
Rajesh Agrawal 28et al., (2010) studied the Granulation of a powder or mixture of 
powder is done in order to improve flow, uniformity of contents better 
compressibility, improve density and to aid pharmaceutical dosing of the actives. 
The review article updates about the latest developments in technologies behind 
most commonly used wet granulation process. Article deals with in depth basic 
information about granule growth mechanisms during granulation. The article also 
provides an insight to the in-process variables and factors influencing the 
granulation end point and its determination when a high shear mixer granulator of 
laboratory commercial scale is utilized for industrial production. 
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Shirsand SB29 et al., (2010) studied the fast disintegrating tablets of 
Prochlorperazine Maleate was designed with a view to enhance patient compliance 
by direct compression method. In this method crospovidone (3%w/w) and 
croscarmellose sodium up to 5%w/w in combination were used as super 
disintegrants. 
Narasimhan30 (2009) reported a serious hand-and-foot syndrome in black patients 
treated with Capecitabine. It is one of the well-known adverse events associated 
with Capecitabine,a prodrug of 5-Fluorouracil (5-FU).HFS,also known as 
erythrodysesthesia, manifests as acral erythema with swelling and dysesthesia of 
the palms and plantar aspects of the feet and in the absence of dosage reduction or 
stoppage of the drug, progresses to moist desquamation and ulceration with 
serious infections and loss of function. In black patients, we observed 
that Capecitabine given in the recommended dosage leads to hyper pigmentation of 
the palms and soles, followed by a distinct keratoderma like thickening not seen in 
white patients. 
Abhay Gupta31 et al., (2009) the correlation between disintegration and 
dissolution for Immediate release tablets containing a high solubility drug and to 
identify formulations where disintegration test, instead of the dissolution test, may 
be used as the acceptance criteria based on International Conference on 
Harmonization  guidelines. 
 Sagar Bhise32 et al., (2009) The super disintegrants acts as hydrophilic carrier for 
poorly water insoluble drug. So this present article investigates the solubilizing 
properties of super disintegrants and hence enhancement of the dissolution profile 
of a model drug furosemide (poorly water insoluble) using solid dispersion (SD) 
with crosspovidone, crosscarmellose sodium and sodium starch glycolate (SSG) by 
using kneading technique. The 1:1 (w/w) and 1:2 (w/w) solid dispersions were 
prepared by kneading method using solvent water and ethanol in 1:1 ratio. 
Dissolution studies using the USP paddle method were performed for solid 
dispersions of Furosemide at 37 ± 0.5oC and 50 rpm in simulated gastric fluid 
(SGF) of pH 1.2. Fourier transformer Infrared (FTIR) spectroscopy, Differential 
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scanning calorimetry (DSC), and X-ray diffractometry (XRD) were performed to 
identify the physicochemical interaction between drug and carrier, hence its effect 
on dissolution. IR spectroscopy, XRD, and DSC showed change in the crystal 
structure towards amorphous one of Furosemide (FRMD). Dissolution of 
Furosemide improved significantly 1:2 solid dispersion indicated increase in 
dissolution 5.40 fold. From this study it was concluded that the solubility and 
dissolution of model drug Furosemide was increased due to solid deposition of 
drug upon surface of hydrophilic and strongly swelling super disintegrants which 
enhanced the wettability and dispersibility of poorly water soluble drug 
Furosemide which is prerequisite step for poorly water soluble drug. 
Sekar33 et al., (2009) developed immediate release tablets of Telmisartan which is 
anti –Hypertensive drug of BCS class-2 by using Crospovidone as a intragranular 
and extragranular level of addition to increase the rate of drug release from the 
dosage form to increase dissolution rate and hence its bioavailability. It was found 
that Immediate release tablets with proper hardness disintegration time and with 
increase rate of dissolution can be made using polyplasdone XL-10. 
Rai K34 et al., (2009) developed immediate release tablets of Raloxifen 
hydrochloride by wet granulation method. Raloxifen was formulated as Immediate 
release tablets by using different binders like ethyl cellulose, HPMC and various 
disintegrants like crospovidone and croscarmellose sodium .The optimized formula 
shows good in vitro  drug release of 87% within 45 minutes. 
Jain C P35 et al., (2009) investigated on formulation and evaluation of fast 
dissolving tablets of Valsartan, in this investigation fast dissolving tablets of 
Valsartan were prepared using different super disintegrants by direct compression 
method.   The drug release from FDT’s increased with increasing concentration of 
super disintegrants and was found to be highest with formulations containing 
Crospovidone .In the present study it can be concluded from the characterization of 
fast dissolving tablets of Valsartan that formulation containing Crospovidone is 
most acceptable. 
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Pani36 et al., (2008) developed immediate release tablets of Nateglinide and were 
formulated by using various proportions of different super disintegrants such as 
croscarmellose sodium, sodium starch glycolate, kyron by non-aqueous wet 
granulation technique. It was indicated that the Immediate release tablets of 
Netaglinide can be formulated by using optimum concentration of kyron, sodium 
starch glycolate and croscarmellose sodium. Good correlation was established 
between in vitro dissolution time and rate for each of three super disintegrants at 
that concentrations were studied. 
Mallikarjuna Settee C37, et al., (2008) Aceclofenac fast dispersible tablet have 
been prepared by wet granulation method. Effect of super disintegrants such as 
croscarmellose sodium,  sodium starch glycolate and Crospovidone on wetting 
time, disintegration time, drug content, in vitro release. The disintegration time and 
dissolution parameters increased with the increase in level of sodium starch 
glycolate. 
Babu38 et al., (2007) have prepared solid dispersions of Piroxicam in five super 
disintegrants namely primogel, microcrystalline cellulose, crospovidone, 
pregelatinized starch, croscarmellose sodium and with water soluble carriers 
polyvinyl pyrolidone and polyethylene glycol. Solid dispersions of Piroxicam in 
super disintegrants gave a marked enhancement in its dissolution rate and 
dissolution efficiency. Solid dispersion in super disintegrants could be used as an 
effective and efficient technique for enhancing the dissolution rate of Piroxicam a 
poorly soluble drug. 
Honary39 et al., (2007) has studied the effect of film coating solution containing 
different grades of HPMC (E5,E15 and E50) with and without polyethylene glycol 
(with various molecular weights), for the characterization of pharmaceutical 
products. 
Sunil A. Agnihotri40 et al., (2006) This paper describes the synthesis of 
Capecitabine-loaded semi-interpenetrating network hydrogel microspheres of 
chitosan-poly (ethylene oxide-g-acrylamide) by emulsion crosslinking using 
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glutaraldehyde. Poly (ethylene oxide) was grafted with polyacrylamide by free 
radical polymerization using ceric ammonium nitrate as a redox initiator. 
Capecitabine, an anticancer drug, was successfully loaded into microspheres by 
changing experimental variables such as grafting ratio of the graft copolymer, ratio 
of the graft copolymer to chitosan, amount of cross linking agent and percentage of 
drug loading in order to optimize process variables on drug encapsulation 
efficiency, release rates, size and morphology of the microspheres. A 24 full 
factorial design was employed to evaluate the combined effect of selected 
independent variables on percentage of drug release at 5 h (response). Grafting, 
interpenetrating network formation and chemical stability of the Capecitabine after 
encapsulation into microspheres was confirmed by Fourier infrared spectra (FTIR). 
Differential scanning calorimetry (DSC) and X-ray diffractometry (XRD) studies 
were made on drug-loaded microspheres to investigate the crystalline nature of 
drug after encapsulation. Results indicated amorphous dispersion of Capecitabine 
in the polymer matrix. In vitro release studies were performed in simulated gastric 
fluid (pH 1.2) for the initial 2 h, followed by simulated intestinal fluid (pH 7.4) 
until complete dissolution. The release of Capecitabine was continued up to 10 h. 
Eric Beyssac41 et al., (2006) The drug studied was Acetaminophen in the form of 
Immediate release (IR) tablets. The second purpose was to establish a level A  
in vitro/in vivo correlation that could predict the bioavailability of a drug instead of 
using difficult, time-consuming and expensive in vivo bioequivalence studies. The 
artificial digestive system was used to estimate the availability of Acetaminophen 
IR tablets for absorption in fasted and fed states. The same study was performed in 
vivo under similar conditions.  Compared to USP II method, the novel in vitro 
model demonstrated a high level of efficacy in mimicking the behavior of 
Acetaminophen IR tablets in vivo in fasted and fed states. 
Bhagawati42et al., (2005) formulated Cefixime with various disintegrants like 
croscarmellose sodium, sodium starch glycolate and crospovidone and using starch 
and PVP K30 as binders. They used direct compression as the method of 
preparation of tablets. Even though the mean disintegration time decrease with 
sodium starch glycolate and Crospovidone. 
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Prakash K43et al., (2005) studied on formulation and evaluation of Metronidazole 
fast dispersible tablets using some disintegrants such as potato starch, 
pregelatinised starch, sodium starch glycolate and microcrystalline cellulose. 
Starchpaste (10%) was used as binding agent and concluded that dispersible tablets 
of Metronidazole prepared using primojel as disintegrant showed rapid 
disintegration, dissolution rates compared to other formulations. 
 
Stan forth44et al., (2004) studied the microcrystalline cellulose excipient having 
improved compressibility whether utilized in direct compression dry granulation or 
wet granulation and possess excellent disintegrating and dissolution properties 
when exposed to gastrointestinal fluid. 
 
Mira Jivraj45 et al., (2000) studied that many formulation scientists ranked 
microcrystalline cellulose as the most useful filler for direct compression. It reveals 
that the popularity ascribed to its excellent compactibility at low pressures, high 
dilution potential and superior disintegration properties. This study concluded that 
as a result of its low bulk density, microcrystalline cellulose has a high dilution 
potential. 
 
Tang46 (2000) has studied the effect of film coating on the release of 
Chloramphenicol maleate tablets and was observed that film coating of aqueous 
solution of hydroxylpropyl methyl cellulose improves the dissolution profile. It 
was found that the increased dissolution rate is due to the easy penetration of 
solvent into the HPMC, which helps in wetting of core tablet. 
 
Preetha47 (2000) has studied the effect of mode of incorporation of super 
disintegrants such as croscarmellose sodium, sodium starch glycolate and 
Crospovidone on dissolution. The results indicated that the formulation containing 
croscarmellose sodium has shown best release profile than the other super 
disintegrants due to rapid swelling action of the polymer. 
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                                         3. Aim and Objective 
              The object of the present research is to produce a generic tablet which was 
robust, stable and of an acceptable formulation when compared to the reference 
original product, thereby fulfilling the requirements of essential similarity to the 
innovator or reference product. 
              The investigation is concerned with development of Capecitabine 
Immediate release dosage (IR) form, which can be used for the treatment of 
colorectal carcinoma and breast cancer. 
               The Immediate Release tablet dosage form of Capecitabine prepared by 
Direct compression and Wet Granulation technique to compare and evaluate the  
in vitro drug release profile of the formulation. Another object of the investigation 
is to include the super disintegrant with different concentration as the intra-
granular and extra-granular agent to facilitate the drug release. 
              The prepared dosage form to be tested for physical characteristics of 
tablet, and In vitro drug release study, Dissolution efficiency (DE), Determination 
of similarity factor (f1, f2), Stability study with respect to the innovator drug 
product. 
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4. Plan of Work: 
The present research work relates to development of immediate release 
tablets of Capecitabine by direct compression and wet granulation methods using 
HPMC, SSG, MCC and Lactose anhydrous and comparision of the in vitro 
dissolution profile of Capecitabine with that of the innovator Xeloda. 
 
4.1. The schematic representation for Plan of Work: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure No 3: Plan of work-schematic representation 
 
 
 
Preformulation Studies: 
 API characterization         
 Compatibility studies 
(For drug & Excipients) 
Preparation of Tablets: 
 Direct Compression and 
wet granulation of 
Tablets 
Evaluation of physical 
parameters: 
 Weight variation 
 Thickness 
 Hardness 
 Friability 
 Disintegration 
 Drug Content  
Uniformity test etc. 
 In vitro Evaluation by 
dissolution profile. 
 
 Selection of Optimized Formulation 
 Stability study by ICH guidelines for 
optimized formulation. 
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5. Drug and Excipient profile 
5.1 Drug profile: 48, 49 
 
Name                               :    Capecitabine 
 
Structure                          : 
 
 
IUPAC Name : Pentyl[1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-
fluoro-2-oxo-1H pyrimidin-4-yl]carbamate 
Molecular 
Formula 
: C15H22FN3O6 
Molecular 
Weight 
: 359.35 
Melting point 
LogP                         
: 
:
110-121° C 
0.4 
Solubility : It is soluble in water (26mg/ml) 
Category : Antineoplastic. 
T½ : Approximately 38-45 minutes. 
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Dose : The usual starting dose is 2,500 mg/m2/day in two divided 
doses, 12 hours apart. One cycle includes two weeks of 
treatment followed by one week without treatment. Cycles 
can be repeated every three weeks. 
BCS : Class Type III (High solubility, Low permeability) 
 
Pharmacokinetics: 
Absorption:  
               Readily absorbed through GI tract (approximately 70%). Time to reach 
peak plasma concentration for Capecitabine is approximately 1.5 hours and for 5-
fluorouracil is 2 hours. Food decreased peak plasma concentration is 60% and area 
under curve is 35% for Capecitabine and decreased peak plasma concentration 
(cmax) 4.3% and  area under curve 21% for 5-fluorouracil.Food delayed Tmax is 
1.5hours. 
Protein binding: 
                Less than 60% protein binding (mainly albumin). 
Metabolism: 
              Metabolized by thymidine phosphorylase to fluorouracil. 
Elimination: 
            Capecitabine and its metabolites are predominantly excreted in urine. 
About 95.5% of administered Capecitabine dose is recovered in urine. Fecal 
excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL 
which represents 57% of the administered dose. About 3% of the administered 
dose is excreted in urine as unchanged drug. 
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Mechanism of Action:  
               Capecitabine is a prodrug that is selectively tumour-activated to its 
cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in 
higher concentrations in many tumors compared to normal tissues or plasma. 
Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-
deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate 
(FUTP), within normal and tumour cells. These metabolites cause cell injury by 
two different mechanisms. First, FdUMP and the folate cofactor, N5-10-
methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently 
bound ternary complex. This binding inhibits the formation of thymidylate from 2'-
deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, 
which is essential for the synthesis of DNA, therefore a deficiency of this 
compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can 
mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the 
synthesis of RNA. This metabolic error can interfere with RNA processing and 
protein synthesis through the production of fraudulent RNA. 
Indications and usage:  
              Capecitabine is a nucleoside metabolic inhibitor with anti-neoplastic 
activity. It is used in the treatment of 
 Adjuvant colon cancer Stage III Dukes' C - used as first-line monotherapy. 
 Metastatic colon rectal cancer 
- First line as monotherapy when treatment with fluoro pyrimidine 
monotherapy alone is preferred. 
 Metastatic breast cancer 
-as monotherapy, if the patient has failed paclitaxel based treatment, and if 
anthracycline based treatment has either failed or cannot be continued for 
other reasons. 
-used in combination with docetaxel, after failure of anthracycline based 
treatment. 
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Adverse reactions: Most common adverse reactions are 
 Cardiovascular    : EKG changes, myocardial infarction, angina. 
  Dermatological  :  Hand and foot syndrome. 
  Gastrointestinal  : Diarrhea, Nausea, stomatitis. 
  Hematological    : Neutropenia, anemia and thrombocytopenia 
  Hepatic               : Hyperbilirubinemia. 
Drug interactions: 
 Anticoagulants  : May interact with warfarin and increase bleeding risk. 
 Phenytoin          :. May inhibit cytochrome CYP2C9 enzyme, and therefore 
increase levels of substrates such as Phenytoin and other substrates of   
CYP2C9 
 Leucovorin     : The concomitant use of Leucovorin is not recommended. 
Leucovorin increased the toxicity of Capecitabine without any apparent 
advantage in response rate. 
Pharmacodynamics: 
      Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity 
indicated for the treatment of metastatic breast cancer and colon cancer. It is an 
orally administered systemic prodrug that has little pharmacologic activity until it 
is converted to fluorouracil by enzymes that are expressed in higher concentrations 
in many tumors. Fluorouracil it then metabolized both normal and tumor cells to 5-
fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine 
triphosphate (FUTP). 
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5.2Excipient profile: 
5.2.1 Hydroxypropyl Methyl Cellulose (HPMC): 50 
      Non-proprietary names: 
IP : Hydroxypropylmethlcellulose 
BP : Hypromellose 
Ph Eur : Methylhydroxypropylcellulosm 
USP : Hypromellose 
    Synonyms 
Benecel MHPC; E464; Hydroxypropyl Methylcellulose; HPMC; Methocel; 
methylcellulose Propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose; Tylopur. 
    Chemical Name and CAS Registry Number 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
    Molecular structure: 
          
   Functional Category:  
        Coating agent, film former, rate controlling polymer for sustain release, 
stabilizing agent, suspending agent, tablet binder, viscosity increasing agent. 
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Description: 
          Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
Applications in Pharmaceutical Formulation or Technology: 
          Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, HPMC is primarily used as a tablet binder (1), in 
film-coating,(2–7) and as a matrix for use in extended-release tablet 
formulations.(8–12) Concentrations between 2% and 5% w/w may be used as a 
binder in either wet- or dry-granulation processes. Hypromellose at concentrations 
between 0.45–1.0% w/w may be added as a thickening agent to vehicles for eye 
drops and artificial tear solutions. Hypromellose is also used as an emulsifier, 
suspending agent, and stabilizing agent in topical gels and ointments. As a 
protective colloid, it can prevent droplets and particles from coalescing or 
agglomerating, thus inhibiting the formation of sediments. In addition, 
hypromellose is used in the manufacture of capsules, as an adhesive in plastic 
bandages, and as a wetting agent for hard contact lenses. It is also widely used in 
cosmetics and food products. 
Incompatibilities: 
Hypromellose is incompatible with some oxidizing agents. Since it 
isotonic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates. 
Stability and Storage Conditions 
          Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the 
viscosity of solutions. Hypromellose undergoes a reversible sol–gel transformation 
upon heating and cooling, respectively. The gel point is 50–90°C, depending upon 
the grade and concentration of material. 
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Hypromellose powder should be stored in a well-closed container, in a cool, dry 
place. 
Safety: 
        Hypromellose is generally regarded as a nontoxic and nonirritating material, 
although excessive oral consumption may have alaxative effect. 
5.2.2 Sodium starch glycolate: 51 
Non proprietary name: 
       BP:  Sodium starch glycolate;  
       USPNF:  Sodium starch glycolate. 
Synonyms:  
       Explotab, Primogel 
Functional category:   
       Tablet and capsule disintegrant. 
Chemical names:  
       Sodium carboxymethyl starch 
CAS Registry Number:  
       9063-38-1 
Structure: 
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Description: 
       Sodium starch glycolate is a white to off-white, odourless, tasteless, free 
flowing powder. It consists of oval or spherical granules, 30-100 μm in diameter 
with some less spherical granules ranging from 10-35 μm in diameter. 
Solubility: 
      Practically insoluble in water. Sparingly soluble in ethanol (95%). In water it 
swells up to 300 times its volume. 
Stability and storage conditions: 
       It is a stable material. It should be stored in a well closed container to protect 
from wide variations in humidity and temperature that may cause cracking. 
Incompatibilities:  
       Incompatible with ascorbic acid. 
Safety:  
      It is generally regarded as a non-toxic and non-irritant material. However, oral 
ingestion of large quantities may be harmful. 
Applications:  
      As a disintegrant in tablet (wet granulation and direct compression and capsule 
formulation in 2-8% concentration. 
5.2.3 Lactose anhydrous: 52 
Nonproprietary Names: 
       BP :  Anhydrous Lactose 
       JP  :  Anhydrous Lactose 
       PhEur :  Lactose, Anhydrous 
       USP-NF :  Anhydrous Lactose 
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 Synonyms: 
          Anhydrous 60M; Anhydrous Direct Tableting (DT); Anhydro  DT High 
Velocity; Anhydrous Impalpable; Lactopress Anhydrous;Lactopress Anhydrous 
250; lactosum anhydricum; lattosio; milksugar; SuperTab 21AN; SuperTab 
22AN; saccharum lactis. 
Chemical Name: 
           O-b-D-Galactopyranosyl-(1→4)-b-D-glucopyranose 
Empirical Formula:  
             C12H22O11 
Structure: 
                
Molecular weight: 
                342.3 
Functional Category: 
             Directly compressible tablet excipient; dry powder inhaler carrier; 
lyophilization aid; tablet and capsule diluent; tablet and capsule filler. 
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Applications in Pharmaceutical Formulation: 
             Anhydrous lactose is widely used in direct compression tableting 
applications, and as a tablet and capsule filler and binder. It can be used with 
moisture-sensitive drugs due to its low moisture content. It may also be used in 
intravenous injections. 
Description: 
            Anhydrous lactose occurs as white to off-white crystalline particles or 
powder. Typically contains 70–80% anhydrous b-lactose and 20–30% anhydrous 
a-lactose. 
Solubility: 
            Soluble in water; sparingly soluble in ethanol (95%) and ether; 40 
g/100mL at 258C for typical Sheffield Pharma Ingredients Products. 
 Stability and Storage Conditions: 
               Mold growth may occur under humid conditions (80% RH and above). 
It can be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
               Lactose anhydrous is incompatible with strong oxidizers. This 
accelerates the hydrolysis of the ester and amidine groups. Lactose anhydrous is a 
reducing sugar with the potential to interact with primary (5) and secondary 
amines (6) (Maillard reaction) when stored under conditions of high humidity for 
extended periods. 
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5.2.4 Microcrystalline cellulose (Avicel pH 112): 53 
Non Proprietary Names 
BP              :    Microcrystalline Cellulose 
JP               :    Microcrystalline Cellulose 
PhEur         :    Cellulose, Microcrystalline 
USP-NF     :   Microcrystalline Cellulose 
Synonyms: 
         Avicel pH; Celex; Cellulose gel; hellulosum microcristallinum; Celphere; 
Ceolus KG; crystalline cellulose; E460; Emcocel; ethispheres . 
Chemical Name:  
       Cellulose 
Empirical Formula and molecular weight: 
        (C6H10O5) n ≈ 36000 where n ≈220 
Molecular structure: 
            
Functional Category:  
        Adsorbent; suspending agent; as a diluents in tablets and capsules; tablet 
disintegrant. 
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Description:  
        Microcrystalline cellulose is a purified partially depolymerised cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture 
grades that have different properties and applications. 
Stability and Storage Conditions 
      Microcrystalline cellulose is a stable through hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
      Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Applications 
      Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
binder/diluents in oral tablet and capsule formulations where it is used in both wet- 
granulation and direct-compression processes. In addition to its use as 
binder/diluents, microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting. 
Safety:  
     Generally regarded as safe. 
5.2.5 Magnesium stearate: 54 
Non-proprietary names:  
BP  :  Magnesium stearate  
JP  :  Magnesium stearate  
PhEur  :  Magnesiistearas 
USPNF :  Magnesium stearate  
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Synonyms: 
        Magnesium octadecanoate, octadecanoic acid magnesium salt and stearic acid 
magnesium salt.  
Chemical name: 
       Octadecanoic acid magnesium salt  
Structural formula: 
       [CH3 (CH2)16COO] 2Mg  
Molecular Structure: 
 
Molecular weight: 
        591.34  
Functional category: 
       Tablet and capsule lubricant. 
 
Melting point: 
        117-1500C  
Description: 
       Magnesium stearate is a fine, white, precipitated or milled, impalpable powder 
of low bulk density, having a faint odor of stearic acid and a characteristic taste. 
The powder is greasy to touch and readily adheres to the skin.  
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Solubility: 
       It is practically insoluble in ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%).  
Applications: 
       It is widely used in cosmetics, foods and pharmaceutical formulations. It is 
primarily used as a lubricant in the manufacturing of tablets and capsules, in the 
concentration of 0.25-5.0%. It is also used in barrier creams.  
Stability and storage conditions: 
         It should be stored in a well closed container in a cool, dry place.  
Incompatibilities: 
          It is incompatible with strong oxidizing agents, strong acids, alkalis and iron 
salts. It cannot be used in products containing aspirin, some vitamins and most 
alkaloidal salts.  
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6. Materials and Methods 
6.1 Materials and Instruments 
6.1.1 Materials 
Table No 2: List of Materials and Suppliers 
 
   S. No 
 
            Materials  
 
     Manufacturer/Supplier 
    1 Capecitabine 
 Aarthi drugs private limited 
 Mumbai, India. 
    2 Anhydrous lactose 
Signet pharma agencies,  
Mumbai, India. 
    3 
Microcrystalline cellulose 
(Avicel pH 112) 
Signet pharma agencies,  
Mumbai, India. 
    4 
HPMC E-5 
(Hypromellose E-5) 
Signet pharma agencies,  
Mumbai, India. 
   5 Magnesium stearate 
Signet chemical corporation, 
Mumbai, India. 
   6 Opadry pink 
Ideal cures Pvt. Ltd 
Mumbai, India. 
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6.1.2 Instruments 
             
Table No 3: List of Instruments and Suppliers 
S. 
No 
Instruments Manufacturer/Supplier 
1 Digital balance Mettler Toledo dr-203, Switzerland 
2 Sieves Jayanth test sieves. Mumbai 
3 Kalweka blender Cadmach machinery co.pvt.lt, 
Ahmadabad 
4 Mini rotary tablet punching 
machine 
REMEC, mini press, Ahmadabad 
5 Friabillator Electro lab EF-2, Friabillator (USP), 
Mumbai 
6 Hardness tester Electro lab, Mumbai 
7 Digimatic vernier calipers Electro lab, Mumbai 
8 Tray drier Platinum pharma tech. Hyderabad 
9 Disintegration tester Electrolab, Mumbai 
10 Digital tablet dissolution 
apparatus USP 
Electrolab, Mumbai 
11 Tap density apparatus Electrolab, Mumbai 
12 Electromagnetic sieve shaker Electro pharma, Mode EMS-8, Mumbai 
13 Ultra Sonicator Electro lab, Mumbai 
14 Mechanical stirrer Remi motors, Mumbai 
15 UV/Visible spectro-photometer Electro lab, Mumbai 
16 Halogen Moisture Analyzer 
(LOD) 
Mettler Toledo 
17 FBD (Fluid bed drier) U Mong Pharma tech pvt.ltd Mumbai 
18 pH meter  Electro lab, Mumbai 
19 Hot air oven Elket motors, Mumbai 
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6.2. Methods: 
6.2.1 Preformulation Studies55,56,57 
          Preformulation may be described as a stage of development during which the 
physicochemical and biopharmaceutical properties of a drug substance are 
characterized. It is an important part of the drug development process. The 
information relating to drug development acquired during this phase is used for 
making critical decisions in subsequent stages of development. A wide variety of 
information must be generated to develop formulations rationally. Characterization 
of the drug is a very important step at the preformulation phase of product 
development followed by studying the properties of the excipients and their 
compatibility.  
6.2.1.1 Angle of repose: 
 Angle of Repose is defined as the maximum angle possible between the 
surface of a pile of the powder and the horizontal plane. The angle of repose is 
determined by funnel method. The funnel is fixed at a particular height (2.5 cm) on 
a burette stand. The powder sample was passed through the funnel allowing it to 
form a pile. No more granules are added as the pile touches the tip of the funnel. 
This region is encircled to measure radius. The same procedure is done for 
triplicate, the average value is taken. The values are given in table28The angle of 
repose is calculated by using equation. 
 
 
Where, 
 h = height of pile 
 r = radius of the base of the pile 
 θ = angle of repose 
  
Angle of Repose (θ) =Tan -1 (h/r) 
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                  Table No 4: Angle of repose and corresponding flow properties 
Angle of Repose Flow property 
<25 
25-30 
30-40 
>40 
Excellent 
Good 
Passable 
Very Poor 
 
6.2.1.2 Bulk density determination: 
 Weighed quantity of the powder (W) is taken in a graduated measuring 
cylinder and volume (V0) is measured, the readings were shown in Table 28. Bulk 
density is calculated using the formula 
6.2.1.3 Tapped density determination: 
Weighed quantity of powder (W) is taken in a graduated cylinder and the volume 
is measured. The graduated cylinder was fixed in the ‘Tapped Densitometer’ and 
tapped for 500, 750 and 1250 times until the difference in the volume after 
consecutive tappings was less than 2%.  The final reading was denoted by (Vf). 
The volume of blend was used to calculate the tapped density, Hausner’s ratio and 
Carr’s Index. 
 
  
Bulk density (BD) = Weight of the powder/ Volume of powder 
Tapped density (TD)  = W/Vf g/ml 
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6.2.1.4 Carr’s Index: 
Carr’s index is also known as compressibility. It is indirectly related to the relative 
flow rate, cohesiveness and particle size. It is simple, fast and popular method of 
predicting powder flow characteristics. 
Table No 5: Carr’s Index and corresponding flow properties 
 
 
 
Carr’s index was calculated by using the formula: 
 
    Carr’s Index   =  (Tapped Density –Bulk Density) x   100                                                
                                                   Tapped Density 
 
6.2.1.5 Hausner ratio: 
Hausner ratio indicates the flow properties of the powder and measured by the ratio 
of tapped density to bulk density.  The relationship between Hauser’s ratio and 
flow property was shown in Table No 6. 
           
Carr’s Index (%) Flow 
5-15 
16-18 
18-21 
23-35 
33-38 
>40 
Excellent 
               Good 
Fair to passable 
Poor 
Very poor 
Very very poor 
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              Table No 6: Hausner ratio and corresponding flow properties 
Hausner Ratio Property 
0-1.2 Free flowing 
1.2-1.6 Cohesive Powder 
 
 Hausner ratio was calculated by using the formula.  
Hausner Ratio   =   Tapped density / Bulk density 
Hausner Ratio    =    V0/Vf 
                                              
where,   V0= Initial volume  
               Vf = Final volume 
 6.2.1.6 Compressibility Index (% Compressibility): 
Carr’s compressibility index i.e., % compressibility indicates the flow property and 
packing ability of the tablet. It is determined by measuring both the bulk and 
tapped density of a powder. When the % compressibility ranges from 5 to 16, the 
materials have acceptable flow property and packing ability. Compressibility Index 
was calculated using following equation: 
CI (%) = [(Dt -Db)/Dt] x100 
 
Where, 
 Dt = tapped density,  
Db = bulk density 
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                    Table No 7:  Acceptance criteria of flow properties 
Compressibility Index Flow Character Hausner Ratio 
1 – 10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very Poor 1.46 – 1.59 
> 38 Very Very Poor > 1.60 
 
6.2.1.7 Drug excipient interaction studies (FT-IR): 
          Infrared spectroscopy is one of the most powerful analytical technique when 
it comes to the determination of presence of various functional groups involved in 
making up the molecule. It provides very well accountable spectral data regarding 
any change in the functional group characteristics of a drug molecule occurring in 
the process of formulation.IR spectra of capecitabine and its formulation were 
obtained by KBr pellet method using Perkin Elmer spectrum RX1 FT-IR 
spectrophotometer model. 
 
 
 
 
 
 
 
 
  
59 
 
6.2.2 Preparation of tablets 
6.2.2.1 Preparation of Tablets by direct compression: 
Step 1:  Sifting of the drug and the excipients 
Capecitabine, Microcrystalline cellulose, Lactose anhydrous, Sodium starch 
glycolate and HPMC were weighed and sifted individually through 40 # mesh. 
Step 2:  Mixing 
All the ingredients were transferred to poly bag and mixed for 10 min and blend 
was passed through 40 # mesh and mixed thoroughly. 
Step 3: Blending and Lubrication 
Magnesium stearate used as a lubricant was weighed, added and blended with the 
ingredients for 5 min. 
Step 4:  Compression and Coating 
The mixture was compressed and film coated with Opadry pink. 
6.2.2.2 Preparation of Tablets by wet granulation: 
Step 1:  Sifting of the drug and the excipients 
Ingredients such as API, Microcrystalline cellulose, Lactose anhydrous and 
Sodium starch glycolate are sifted individually through 40 # mesh. 
Step 2:  Mixing 
All the ingredients were transferred to poly bag and mixed for 10 min and blend 
was passed through 40 # mesh and mixed thoroughly. The binder solution was 
prepared by dissolving HPMC in sufficient quantity of purified water and added to 
the blend. 
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Step 3: Drying 
The wet mass was passed through 12 # mesh and the granules obtained were dried 
at 600C for 30 min. 
Step 4: Compression and coating 
The prepared granules were lubricated with magnesium stearate and sodium starch 
glycolate is added as extragranular agent and passed through 40 # mesh and was 
compressed by using punches. Tablets obtained were coated using Opadry pink. 
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      Table No 8: Composition of Capecetabine Immediate Release tablets 
Batch No F1 F2 F3 F4 F5 F6 F7 F8 F9 
S.No 
Ingredients 
(mg/Tab) 
DC WG WG WG WG WG WG WG WG 
1 Capecitabine 500 500 500 500 500 500 500 500 500 
2 
Lactose 
Anhydrous 
105.5 101 92 92 88 86 85 83 83 
3 SSG 10 12 15 10 9 7 6 6 6 
4 HPMC E5 15 15 18 18 20 20 20 20 20 
5 
Purified 
Water 
0 QS QS QS QS QS QS QS QS 
6 
MCC 
pH 112 
12 12 15 15 15 15 15 15 115 
7 SSG 0 0 0 5 8 12 14 16 16 
8 Mg stearate 7.5 10 10 10 10 10 10 10 10 
9 Opadry pink 15 15 15 15 15 15 15 15 15 
 Total 665 665 665 665 665 665 665 665 665 
 
 DC- Direct Compression        
 WG-Wet Granulation 
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6.2.3 Evaluation Parameters58,59:  
6.2.3.1 General Appearance and Organoleptic Properties 
The control of a general appearance of a tablet involves the measurement of a 
number of attributes such as a tablet’s shape, size, colour, presence or absence of 
an odor, taste, surface texture, physical flaws and consistency, and legibility of any 
identifying markings. 
6.2.3.2 Shape, Thickness and Dimension 
Six tablets from each batch were selected and measured for thickness and diameter 
using digital Vernier calipers. The extent to which the thickness of each tablet 
deviated from ± 5% of the standard value was determined. 
6.2.3.3 Weight variation test: 
Twenty (20) tablets from each batch were individually weighed. The average 
weight and standard deviation were calculated, individual weight of each tablet 
was also calculated using the same and compared with average weight 
Weight Variation limits as per USP and the values were showed in the table. 
 
Table No 9: Weight Variation for solid dosage forms (USP) 
Average weight in mg % ± deviation allowed 
130 or less 10 
130-324                         7.5 
More than 324 5 
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6.2.3.4 Hardness test: 
The Monsanto hardness tester was used to determine the tablet hardness. The tablet 
was held between a fixed and moving jaw. Scale was adjusted to zero; load was 
gradually increased until the tablet fractured. The value of the load at that point 
gives a measure of hardness of the tablet. Hardness was expressed in Kg/cm2. 
6.2.3.5 Friability test: 
20 tablets from each batch were selected randomly and weighed. These tablets 
were subjected to friability testing using Roche friabilator for 100 revolutions. 
Tablets were removed, de-dusted and weighed again. Following formula was used 
to calculate the % friability. 
 
%Friability= Initial wt- Final wt / Initial wt x100 
 
6.2.3.6 Disintegration time: 
The test was carried out on 6 tablets using Tablet disintegration tester.  
Distilled water at 37ºC ± 2ºC was used as a disintegration media and the time in 
seconds taken for complete disintegration of the tablet with no palpable mass 
remaining in the apparatus was measured in seconds. 
Disintegration time: 
Uncoated tablet :  Not more than 15 min 
                        Coated tablet  :  Not more than 30 min 
6.2.3.7 Dissolution Studies: 
    Dissolution is process by which a solid state enters a solution. In 
pharmaceutical industry it may be defined as the amount of drug substance that 
goes into solution per unit time under standardised conditions of liquid/solid 
interface, temperature and solvent composition. Dissolution is considered as one of 
the most important QC test performed on pharmaceutical dosage form and is now 
developing into a tool for predicting bioavailability. 
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      Drug release studies of the prepared Capecitabine tablets was performed in a 
USP Dissolution Tester Apparatus, type- II (Paddle method) at 37 ± 0.50C. The 
paddles rotated at a speed of 50 rpm. The tablets were placed into 900 mL of 
deaerated water. Aliquots of 10 ml were withdrawn from the dissolution apparatus 
at different time intervals. The drug content was determined. At each time of 
withdrawal, 10 ml of fresh medium was replaced into the dissolution flask. 
                                 Table No 10: Dissolution conditions 
                         Dissolution conditions 
Medium Deaerated water 
Volume 900ml 
Temperature 37oC ± 0.5oC 
Apparatus USP type –II (paddle) 
RPM  50 
Time interval 5,10, 15, 20,upto 45 minutes 
 
6.2.3.8 Content Uniformity: 
          The content uniformity test is used to ensure that every tablet contains the 
amount of drug substance intended with little variation among tablets within a 
batch. Due to increased awareness of physiological availability, the content 
uniformity test has been included in the monographs of all coated and uncoated 
tablets and all capsules intended for oral administration where the range of size of 
the dosage form available include 500mg or smaller sizes. 
Method: Randomly select 30 tablets. 10 of these assayed individually. The Tablet 
pass the test if 9 of the 10 tablets must contain not less than 85% and not more 
than 115% of the labeled drug content and the 10th tablet may not contain less 
than 75% and more than 125% of the labeled content. If these conditions are not 
met, remaining 20 tablets assayed individually and none may fall outside of the 85 
to 115% range. 
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Assay of Capcetabine:- 
The estimation is done by HPLC. The chromatograph is equipped with; 
                       Column: 4.6mm*25cm with 5micron packing L1 (C18 with 
octadecyl bonded to porous silica or ceramic micro particles) 
                      Refrigerated Auto sampler 
                      Detector  :  250nm detector 
                      Flow rate  :  1ml/min 
                      Column temperature  :  400c 
Mobile phase:- 
Solution-A:- Prepare a mixture of dilute acetic acid, and acetonitrile (60:35:5) 
Solution-B:- Prepare a mixture of methanol, diluted acetic acid, and acetonitrile 
(80:15:5) 
 Diluent :-  Prepare a  mixture of water, methanol, Acetonitrile (60:35:5) 
Standard preparation:- Dissolve an accurately weighed quantity of USP 
Capecitabine RS in diluents, and sonicate if necessary, to obtain a solution having 
a concentration of about 0.6mg per ml. 
Assay preparation: 
             Grind 20 tablets to a fine powder. Dissolve an accurately weighed quantity 
of powdered tablets in diluents, dilute quantitatively with diluents, and sonicate if 
necessary, to obtain a solution having a known concentration of about 0.6mg/ml of 
Capecitabine, based on the label claim. Pass through a PVDF 0.45µm membrane 
filter, and use the filtrate. 
 
 
The chromatograph is programmed as follows:- 
66 
 
                                          Table No 11: Flow program 
Time 
(minutes) 
   Solution A (%)     Solution B (%)               Elution 
0-5 100 0 Isocratic 
5-20 100→49 0→51 Linear gradient 
20-30 49 51 Isocratic 
30-31 49→100 51→0 Linear gradient 
31-40 100 0 Equilibration 
  
Procedure: 
          Separately inject equal volumes (about 10µl) of the standard preparation and 
the assay preparation into the chromatograph, record the chromatograms, and 
measure the response for the Capecitabine peaks. 
6.2.4 Release kinetics60 
 The results of In-vitro release profile obtained for all the formulations 
were plotted in modes of data treatment as follows. 
1. Log cumulative percent drug remaining versus time (first order 
kinetic model)  
 2.  Cumulative percent drug release versus square root of time 
(Higuchi’s model)  
3.  Cumulative percent drug release versus time (zero order kinetic 
model)        
 4. Log cumulative Percent Drug released versus log time 
(Korsmeyers model)  
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 Drug release kinetics-model fitting of the dissolution Data: 
 Whenever a new solid dosage form is developed or produces, it is 
necessary to ensure that drug dissolution occurs in an appropriate manner. Drug 
dissolution from solid dosage forms has been described by kinetic models in which 
the dissolved amount of drug (Q) is a function of the test time, t or Q = f (t). Some 
analytical definitions of the Q (t) function are commonly used such as zero order, 
first order, Higuchi, Korsmeyers-Peppas models. Other release parameters, such as 
dissolution time (tx%), dissolution efficacy (ED), difference factor (f1), similarity 
factor (f2) can be used to characterize drug dissolution / release profile.  
6.2.4.1 Zero-order kinetics:          
 A zero-order release would be predicted by the following equation.  
                  At    =   Ao - Kot            eq ( 1) 
Where,     At    =    Drug release at time t 
 Ao   =     Initial drug concentration 
 Ko   =     Zero-order rate constant (hr) 
                 When the data is plotted as cumulative percent drug release versus time 
if the plot is linear then the data obeys zero-order release kinetics, with a slope 
equal to ko. 
Use:  This relation can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in case of some transdermal 
systems etc. the pharmaceutical dosage forms following this profile release the 
same amount of drug by unit of time and it is the ideal method of drug release in 
order to achieve a prolonged pharmacological action. 
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6.2.4.2 First-order kinetics: 
 A first order release would be predicted by the following equation. 
                  Log C    =      Log Co -  Kt / 2.303          eq(2) 
Where C    =   Amount of drug remained at time t 
 Co  =   Initial amount of drug 
 K    =    First-order rate constant 
 When the data is plotted as log cumulative percent drug remaining 
versus time yields a straight line indicating the release follows first-order kinetics, 
the constant k can be obtained by multiplying 2.303 with slope values 
Use:  The pharmaceutical dosage forms containing water-soluble drugs in porous 
matrices, follows this type of dissolution profile. The release of the drug is 
proportional to the amount of drug remaining in its interior so that the amount of 
drug release by unit of time diminishes 
6.2.4.3 Higuchi model:  
 Drug release from the matrix devices by diffusion has been described by 
following Higuchis classical diffusion equation. 
    Q = [DE/ τ(2A- ECs) Cst ]             eq( 3) 
Where,       Q   =   Amount of drug release at time t 
D   =   Diffusion coefficient of the drug in the matrix 
A    =   Total amount of drug in unit volume of matrix 
Cs   =   Solubility of the drug in the matrix 
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E     =   Porosity of the matrix 
T     =   Time in hrs at which q is the amount of drug is release 
                Equation-3 may be simplified if one assumes that D, Cs and A are 
constant.  Then equation-3 becomes 
    Q    =    K t ½   eq (4) 
 When the data is plotted according to equation-4 i.e. cumulative drug 
release versus Square root of time yields a straight line, indicating that the drug 
was released by diffusion mechanism. The slope is equal to k. 
Use:  The relation can be used to describe the drug dissolution from several types 
of modified release pharmaceutical dosage forms, as in case of some water soluble 
drugs. 
6.2.4.4 Korsmeyer Peppas model:      
 In order to understand the mode of release of drug from swellable 
matrices, the data were fitted to the following equation   
   Mt    /    Mά         = Ktn  eq (5) 
Where,     Mt / Mά         =    Fraction of drug released at time‘t’ 
       K               =     Constant incorporating the structural and geometrical 
                                  Characteristics of the drug/polymer system. 
       n               =      Diffusion exponent related to the mechanism of release. 
The above equation can be simplified by applying log on both sides we get  
  Log       Mt  /   Mά             =     Log K+ n Log t        eq (6) 
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 When the data is plotted as a log of drug released versus log time, yields 
a straight line with a slope equal to n and the k can be obtained from y- intercept. 
 The value of n for a cylinder is <0.45 for Fickian release,  > 0.45 and < 
0.89 for Non-Fickian release, 0.89 for the case 2 release and > 0.89 for  super 
case2 type release. 
6.2.5 Similarity Factor and Dissimilarity Factor Calculation 
 The similarity factor (f2) was defined by CDER, FDA, and EMEA as the 
“logarithmic reciprocal square root transformation of one plus the mean squared 
difference in percent dissolved between the test and Ditropan release profiles”. 
 Dissimilarity or difference factor (f1) describes the relative error 
between two dissolution profiles. It approximates the percent error between the 
curves. The percent error is zero when the test and Ditropan release profiles are 
identical and increases proportionally with the dissimilarity between the two 
profiles. 
 There are several methods for dissolution profile comparison. f2 is the 
simplest among those methods. Moore & Flanner proposed a model independent 
mathematical approach to compare the dissolution profile using two factors f1 & f2. 
 f1 = { [  t=1 nRt – Tt  ] / [  t=1 n Rt ] } . 100  eq (1) 
 f2 = 50. Log { [1 + (1/n)  t=1 n (Rt - Tt ) 2 ] –0.5 . 100}  eq (2) 
 Where 'Rt' and ‘Tt' are the cumulative percentage dissolved at each of 
the selected n time point of the Ditropan & test product respectively. The factor f1 
is proportional to the average difference between the two profiles, where as factor 
f2 is inversely proportional to the averaged squared difference between the two 
profiles, with emphasis on the larger difference among all the time points. The 
similarity factor f2 and its significance is shown in the following  
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6.2.6 Dissolution Efficiency: 
The dissolution efficiency (DE) of a pharmaceutical dosage form (Khan and 
Rhodes, 1972; Khan, 1975) is defined as the area under the dissolution curve up to 
certain time t, expressed as a percentage of the area of  rectangle described by 
100% dissolution in the same time.It can be calculated by the  following equation 
         
            
             
where y is the drug percent dissolved at time t.      
 6.2.7 Stability Study: 
 For all the pharmaceutical dosage forms it is important to determine the 
stability of the dosage form. This will include storage at exaggerated temperature 
conditions, with the necessary extrapolations to ensure the product will, over its 
designed shelf life, provide medication for absorption at the same rate as when 
originally formulated. Specification which is list of tests, reference to the analytical 
procedures and proposed acceptance criteria, including the concept of different 
acceptable criteria for release and shelf life specifications are addressed in ICH 
guidelines. 
             The tablets of the optimized formulation are tested for stability for 3 
months in accelerated and long term test conditions. The tablets are exposed to 
400±20C and 75±5% RH conditions for 3 months. The tablets are observed for 
change in physical appearance, moisture content, assay values, impurities and 
dissolution values at the end of first, second and third month. Stability was 
determined.  
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6.3 Innovator product details: 
         Table No:12 Innovator Details 
Product  Name XELODA 
Label Claim 500mg  and  150mg 
Composition Each film coated tablet contains 150mg or 500mg of Capecitabine. 
Manufactured by Hoffmann la roche Pharmaceuticals 
Description 
Light peach film coated tablet of 
biconvex,oblong shape with the marking 
‘500’on one side and ‘Xeloda’on the other 
side. 
Thickness 3.54mm 
Storage Stored at 250C 
Dissolution Apparatus USP Type II(Paddle type) 
Dissolution Medium Deaerated Water 
Dissolution Medium 
Volume 
900ml 
Time Points 10,20,30,45 min 
Speed 50 RPM 
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7. Results and Discussion: 
7.1 Preformulation: 
Table No 13: Results of physical characterization of the drug 
S. No Description Result 
1.  Appearance White to yellowish powder 
2.  Odour Characteristic odour. 
3.  Solubility Soluble in water (26mg/ml) 
      
7.2 API characterization: 
Table No 14: Flow Properties of API 
S. No Flow Properties Result 
1. Bulk density (g/ml) 0.298gm/ml 
2. Tapped density (g/ml) 0.506gm/ml 
3. Compressibility index (%) 13.14 
4. Hausner’s ratio 1.13 
5. Angle of repose 31 ̊45 ̓
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7.3. Drug and excipients compatibility studies: 
Table No 15: Drug-Excipient compatibility studies 
S. 
No 
            Ingredients    
Description 
  After 
 2 
weeks 
    After 
   4 weeks 
      
Ratio 
       
Initial 
    
    550C 
  
40+20C/70+5% 
               RH 
1  
Capecitabine 
1 White No 
change 
No change 
2 Micro crystalline    
cellulose 
1 White No 
change 
No  change 
3  
Lactose anhydrous 
1 White No 
change 
No change 
4  
Sodium starch 
glycolate 
1 White No 
change 
No change 
5  
HPMC E5 
1 White No 
change 
No change 
6  
Magnesium stearate 
1 White No 
change 
No change 
7 Capecitabine+Avicel 
(Ph 112) 
1:1 White No 
change 
No change 
8 Capecitabine+Lactose 
anhydrous 
1:1 White No 
change 
No change 
9 Capecitabine+Sodium 
starch glycolate 
1:0.5 White No 
change 
No change 
10 Capecitabine+HPMC 
E5 
1:0.5 White No 
change 
No change 
11 Capecitabine+ 
magnesium stearate 
1:0.25 White No 
change 
No change 
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                      Figure No 4:  FTIR spectrum of Capecitabine 
Figure No 5:  FTIR spectrum of Capecitabine prepared formulation 
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7.4 Flow properties: 
 
Table No 16: Results of flow properties of lubricated blend 
 
 
 
 
 
 
  
Batch 
code 
Angle of 
Repose 
(θ) 
Bulk 
density 
(gm/m) 
Tapped 
density 
(gm/m) 
Compressibility 
index (%) 
Hausner’s 
ratio 
F1 43°21’ 0.624 0.798 21.80 1.27 
F2 37°23’ 0.610 0.763 20.05 1.25 
F3 36°31’ 0.605 0.754 19.76 1.24 
F4 38°22’ 0.614 0.738 16.80 1.20 
F5 34 ̊28 0.616 0.726 15.15 1.17 
F6 32°25’ 0.612 0.714 14.28 1.16 
F7 31°21’ 0.625 0.724 13.67 1.15 
F8 32°28’ 0.625 0.714 12.46 1.14 
F9 32
028’ 0.625 0.714 12.46 1.14 
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7.5 Assay (by HPLC): 
                           
Figure No 6: HPLC chromatogram for Capecitabine standard 
                  
 
Figure No 7: HPLC chromatogram for Capecitabine blank 
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Figure No 8: HPLC chromatogram for Capecitabine sample 
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7.6 Results of evaluation of tablets: 
                       
Table No 17: Evaluation of Tablets 
 
S.No 
Batch 
code 
Weight 
variation 
(mg) 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Friability   
(%) 
Assay 
%w/v 
Disintegration 
(min) 
1. F1 608±0.25 - - - - - 
2. F2 662±0.37 3.64±0.05 7.8±0.23 0.106±0.15 100.1 17min3sec 
3. F3 663±0.24 3.68±0.024 8.0±0.17 0.172±0.03 98.9 16min37sec 
4. F4 662±0.18 3.45±0.019 8.3±0.34 0.122±0.36 98.5 15min16sec 
5. F5 664±0.16 3.48±0.11 8.1±0.14 0.17±0.42 99.2 14min 45sec 
6. F6 663±0.41 3.41±0.035 8.4±0.17 0.13±0.015 98.7 13min12sec 
7. F7 663±0.12 3.47±0.053 8.8±0.38 0.182±0.012 101.8 12 min54sec 
8. F8 664±0.01 3.47±0.016 9.0±0.44 0.18±0.01 99.4 11min 52sec 
9. F9 664±0.05 3.47±0.11 9.0±0.41 0.18±0.05 99.4 11min 52 sec 
10. 
Innov
ator 
665 3.54 9.0 0.0 98.8 12 min 
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                            Figure No 9: Weight variation profile 
 
      
                                       Figure No 10: Hardness profile 
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                                           Figure No 11: Thickness profle 
 
 
                                            Figure No 12: Friability profile  
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7.7 In vitro dissolution studies: 
Table 18: % Drug Release of Capecitabine from F2 to F9  and Innovator 
Product 
 
  
S. No 
Time 
(min) 
F-2 F-3 F-4 F-5 F-6 F-7 F-8 
 
 
F-9 
 
 
Xeloda 
1. 0 0 0 0 0 0 0 0 
 
0 
0 
2. 10 38.6 40.3 46.5 47.2 49.8 52.5 54.2  
54.2 
52.3 
3. 20 70.5 71.6 75.4 78.5 79.4 81.6 80.4  
80.4 
78.8 
4. 30 78.9 80.1 84.5 86.3 88.7 90.3 91.2  
91.2 
89.5 
5. 45 81.2 82.5 88.6 91.4 93.9 96 98.7  
98.7 
97.2 
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Table no 19: Invitro dissolution profile of Capecitabine IR tablets (F2) 
                      
S. No Time 
(min) 
Cumulative % 
drug release 
Cumulative amount of 
drug released (mg) 
1 10 38.6 193 
2 20 70.5 352.5 
3 30 78.9 394 
4 45 81.2 406 
 
 
 
 
 
 
Figure No: 13 Invitro dissolution profile of Capecitabine IR tablets (F2) 
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Table no 20: Invitro dissolution profile of Capecitabine IR tablets (F3) 
    
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount 
of drug released (mg) 
1 10 40.3 201.5 
2 20 71.6 358 
3 30 80.1 400.5 
4 45 82.5 406 
 
 
 
 
 
Figure No 14: Invitro dissolution profile of Capecitabine IR tablets (F3) 
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Table no 21 : Invitro dissolution of Capecitabine IR tablets (F4) 
 
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount 
of drug released 
(mg) 
1 10 40.3 232.5 
2 20 71.6 377 
3 30 80.1 422.5 
4 45 82.5 443 
 
 
 
 
Figure No 15: Invitro dissolution profile of Capecitabine IR tablets (F4) 
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Table No: 22 Invitro dissolution of Capecitabine IR tablets (F5) 
 
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount 
of drug released 
(mg) 
1 10 47.2 236.0 
2 20 78.5 392.5 
3 30 86.3 431.5 
4 45 91.4 457 
 
 
 
 
Figure No 16: Invitro dissolution profile of Capecitabine IR tablets (F5) 
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Table No:23 Invitro dissolution of Capecitabine IR tablets (F6) 
 
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount 
of drug released (mg) 
1 10 49.8 249 
2 20 79.4 397 
3 30 88.7 443 
4 45 91.4 469.5 
 
 
 
 
             
Figure No 17: Invitro dissolution profile of Capecitabine IR tablets (F6) 
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Table No 24: Invitro dissolution of Capecitabine IR tablets (F7) 
 
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount of 
drug released (mg) 
1 10 52.5 262 
2 20 81.6 408 
3 30 90.3 451 
4 45 96 480 
 
 
 
 
            
Figure No 18: Invitro dissolution profile of Capecitabine IR tablets (F7) 
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Table No 25: Invitro dissolution of Capecitabine IR tablets (F8) 
 
S No Time (min) 
Cumulative % 
drug release 
Cumulative amount 
of drug released (mg) 
1 10 54.2 271 
2 20 80.4 402 
3 30 91.2 436 
4 45 98.7 493.5 
 
 
 
 
 
 
Figure No 19: Invitro dissolution profile of Capecitabine IR tablets (F8) 
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Figure No 20: Comparison of dissolution profiles of formulated batches 
 
 
 
Figure No 21: Comparison of Optimized batch with the innovator sample 
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7.8 Determination of release kinetics: 
Table No 26: Release kinetics 
S No Time (min) 
Square 
root of 
time 
Log time 
Cum 
%drug 
release 
Log Cum 
%drug 
release 
Cum % 
drug 
remaining 
Log Cum 
%drug 
remaining 
1 0 0 0 0 0 100 2 
2 10 3.16 1 54.2 1.73 45.8 1.66 
3 20 4.47 1.30 83.5 1.92 16.5 1.21 
4 30 5.48 1.47 91.2 1.95 8.8 0.94 
5 45 6.71 1.65 98.7 1.99 1.3 0.11 
 
 
Dissolution-Zero order kinetics 
 
Figure No 22:formulation F8- Zero order kinetics 
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Dissolution- First order kinetics 
 
Figure No 23: Formulation F8-First order kinetics 
Higuchi 
 
Figure No: 24 Formulation F8-Higuchi model 
y = -0.0413x + 2.051
R² = 0.9874
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Korsmeyer and Peppas 
 
Figure No 25: Formulation F8-KorseMeyer Peppas model 
7.9 Difference Factor (f1) & Similarity Factor (f2) Calculation 
Table No 27: Similarity and Differential factor calculation 
Time 
Innovator 
Rt 
     F-8 
      Tt {Rt-Tt} (Rt-Tt)2 
10 52 54 1.9 3.61 
20 79 80 1.6 2.56 
30 90 91 1.7 2.89 
45 97 99 1.5 2.25 
sum (Rt-Tt) 
sum (Rt-Tt)2 
sum Rt 
  
Similarity factor f2 [ Acceptance Criteria :50- 100] 
Difference factor f1 [ Acceptance Criteria : 0 - 15] 
6.7 
11.31 
317.8 
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7.10 Dissolution Efficiency of IR tablets of Capecitabine 
Table No:28 Dissolution Efficiency  
Formulations DissolutionEfficiency (%)        
F2 73.5 
F3 73.32 
F4 73.78 
F5 73.73 
F6 72.1 
F7 72.5 
F8 72.6 
Xeloda 72.22 
 
7.11 Stability studies: 
      Dissolution of trial F – 8 tablets were comparable with reference product. So 
tablets of this batch were kept for stability studies. After 3 months the physical 
parameters of the tablets were same. Water content and related substance are 
within limits. The tablets were tested for Physical appearance, Assay, Relative 
substances, Dissolution, Moisture content at initial, 1st month, 2nd month and 3rd 
month in Accelerated conditions and at initial and 3rd month for long term test 
conditions 
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 Table No 29: Stability Study data (Accelerated) of Trial F – 08 
 
S. No 
 
Parameters 
 
Specifications 
Test Condition 
40 ± 20C & 75 ± 5% RH 
(Accelerated) 
Day-0 Month-1 Month-2 Month-3 
1. Description 
Light pink 
colored, oblong 
shaped tablets 
debossed with 
NC on one side 
and 500 on other 
side. 
Complies Complies Complies Complies 
2. 
Moisture 
content 
- 1.314 1.324 1.33 1.34 
3. Assay 90-110 100.8 100.2 99.6 98.7 
4. 
Related 
substances 
by HPLC 
 
 
 
 
    
I.Unknown 
impurity 
NMT 0.5 0.175 0.014 0.035 0.025 
II. Total 
impurity 
NMT 2.0 0.189 0.504 0.578 0.782 
5. Dissolution 
NLT than 75% 
at 45 min 
98.4 97.6 97.2 96.9 
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7.Discussion: 
7.1 Preformulation: 
API Analysis: 
         The experimental work started with the preformulation of  raw material 
analysis of Capecitabine. The results of physical characterization of the drug like 
appearance,odour and solubility are given in Table:13. The results shows that 
physical characterization of the drug candidate (API) complies with the USP 
specifications 
        The flow properties of API such as bulk density the tapped density, Carr’s 
index, Hausner’s ratio and angle of repose values were depicted in the Table: 14 
and the results were found to be satisfactory. 
Drug excipient compatibility studies: 
          The physical compatibility studies between drug and excipient were carried 
out at 550C for 2 weeks and at 40+20C/70+5% RH for 4 weeks. The drug and 
excipients are taken in different ratios. The results show that there is no change 
from the initial white colour after 2 and 4 weeks indicating that there is no physical 
incompatibility. Results can be observed from Table: 15 
.          The FTIR spectrum from figure 4, of pure Capecitabine showed bands at 
3522 for O-H stretch,2872 for C-H stretch,C=O at 1718 and N-H at 1614. The 
FTIR spectrum of prepared formulation from figure 5, indicate the absence of any 
interactions between Capecitabine and excipients in the formulation. 
7.2 Preparation of tablets: 
              The tablets were prepared by direct compression and wet granulation 
methods. The F1 formulation is prepared by direct compression method and for the 
formulations from F2 to F9 wet granulation method is used. Two methods were 
used for the formulation to check which is the better method for the drug to get the 
optimized formulation with similar values to the innovator. The tablets are 
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prepared by using different excipients like diluents,binders and super disintegrants. 
Sodium starch glycolate is used as super disintegrant in the formulation. 
7.3 Flow properties of lubricated blend: 
               The prepared granules of all the 9 formulations are taken for the study of 
flow properties. The flow properties of each formulation such as angle of 
repose,bulk density,tapped density,compressibility index and hausners ratio are 
determined and the flow properties are found to be poor for F1 formulation and for 
formulations from F2 to F9 the flow properties are satisfactory. The results are 
shown in Table 16 
7.4 Evaluation of tablets: 
                  The film coated tablets are evaluated for weight variation, thickness, 
hardness, frability, disintegration time and assay values. The results were shown in 
Table: 17.The values are in the range of 662 to 664 mg for weight variation for 
formulations F2 to F9 and 608 mg for formulation F1.Thickness and hardness 
values range from 3.41 to 3.68 mm and7.8 to 9kg/cm2 respectively. Results are in 
the range of 0.10 to 0.18 for friability and 11 to 17 minutes for disintegration of 
tablets. Assay values are in the range of 98% to 101%. 
7.5 Effect of direct compression on Capecitabine Immediate Release tablets: 
                 For F1 formulation direct compression method is used.Dissolution test 
failed because of  low fill weight of tablet. The dry state of the materials during 
mixing may induce static charges and lead to segregation due to which variation in 
weight is observed and dissolution values are not achieved. 
 
7.6 Effect of wet granulation on Capecitabine Immediate Release tablets: 
               Formulations F2 to F9 were prepared by the method of wet granulation 
by taking sodium starch glycolate both as extra and intra granular agent in different 
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concentrations. The flow properties are satisfactory. The evaluation parameters are 
almost similar to that of innovator. Wet granulation showed good effect on 
dissolution release of Capecitabine. 
7.7 Effect of super disintegrant (SSG) on Capecitabine Immediate Release 
tablets: 
         Sodium starch glycolate is taken as intragranular agent from formulation F1 
to F3.It is taken both as intragranular and extragranular agent from formulation F4 
to F9.SSG when taken as extragranular agent increases the wicking property of 
tablet which leads to the increase in dissolution rate.SSG shows more effect on 
drug release from tablets when taken as extragranular agent which can be inferred 
from the values of dissolution profile. 
7.8 Drug release studies: 
                  The in vitro drug release studies for F2 to F9 formulations were 
observed from Table 18.The percentage of drug release at the end of 10,20,30 and 
45 min for formulations fF2 to F9 was determined. The percentage of drug release 
increased from F2 to F9.F8 (optimized formulation) shows 98.7% of drug release 
which is similar to that of innovator. 
7.9 Release kinetic study for optimized F8 formulation: 
 The plot of cumulative percentage drug release as a function of time 
indicates that the formulation does not follow zero order or Korsmeyers Peppas 
model Table: 26 the line of best fit obtained was first order release kinetics (R2 
=0.987) and Higuchi kinetics. 
7.10 Reproducibility batch: 
               To check the reproducibility of batch,F9 batch was prepared with the 
same formula of F8.The drug release at  the end of 10,20 30 and 45 minutes was 
found to be 54.2%,78.8%,91.2%,98.7% respectively. Hence the drug release values 
99 
 
of reproducibility batch are similar to the optimized formulation. Results are 
shown in Table:18 
7.11 Comparision between optimized batch and Innovator: 
               The optimized batch F8 is compared with Xeloda. The drug release 
profile of optimized batch and marketed product was found to be 98.7% and 97.2% 
at the end of 45 minutes.. Table: 18 shows that the formulation F-8 was close to 
the Xeloda release profile. Then similarity factor (f2) was calculated between 
formulation F-8 and Xeloda. Similarity factor was (85); therefore, formulation F-8 
has similar release profile to the Xeloda release.Table 27.The dissolution 
efficiency of all the formulations and innovator product are determined.Dissolution 
Efficiency values are in the range of 72% to 73%.The Dissolution Efficiency of 
optimized formulation is 72.6% and that of the innovator is 72.22% 
7.12 Stability studies:  
               Stability studies were conducted for the formulation F8. The stability 
study was performed at 40±20C /75±5 % RH for 1 to 3 months. The tablets were 
analysed for appearance, moisture content, drug content,impurities and in vitro 
drug release. The overall results showed that the formulation is stable at the end of 
1st,2nd and 3rd months. Results were depicted in Table: 29. 
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8. Summary : 
Chapter 1 begins with a general introduction presenting an overview about 
Immediate Release formulations, advantages, methods of granulation, coating 
technique, mechanism of drug release. An introduction about cancer treatment and 
types are discussed. A brief description about breast and colorectal cancer is 
discussed.  
Chapter 2 described the literature review carried out for carried out for selected 
drug, super disintegrant, other excipients and formulation are reviewed. 
Chapter 3 gives information about Aim and Objective of the formulation 
Chapter 4  Describes schematic diagram of plan of work. 
Chapter 5 gives detailed information about the drug and excipients used in the 
formulation.  
Chapter 6 deals with raw material analysis, drug excipient compatibility, 
procedure for flow properties of lubricated blend and procedure for evaluation of 
tablets are described.   
Chapter 7 shows the results and discussion of all formulations. The raw material 
analysis results meet the specifications of IP. The FTIR studies show that there are 
no interactions between drug and excipients. The flow properties of lubricated 
blend was observed and evaluation of tablets was done. The in vitro drug release of 
formulations from F2 to F9 was observed compared and discussed. Effect of super 
disintegrant SSG when taken as extragranular agent was studied. Maximum drug 
release was observed at the end of 45 min for F8 and F9 formulations Stability 
studies were carried out for F8 formulation by keeping the tablets at 400C ± 20C, 
75% ± 5% RH for 3 months. The physical appearance, moisture content, assay 
values, impurities and dissolution values were not altered much at the end of 1st, 
2nd and3rd months. So the tablets are stable. 
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 9. Conclusion: 
                  In the present work efforts have been made to develop Capecitabine 
Immediate Release (IR) tablets by direct compression and wet granulation 
technique. The drug release profile enhanced using SSG and compared with 
innovator drug product. The results showed that the release of the drug was 
depended on Sodium starch glycolate, super disinttegrant used  at intra-granular 
and extra-granular state.  
            All the parametric evaluations were satisfactory with F8-batch when 
compared with Innovator product. Hence, the Bio-equivalence study under 
progress in our lab for optimized Batch Formulation(F8). 
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